1
|
Tedeschi A. SARS-CoV2 infections in heart transplant recipients: Vaccines still are our greatest weapon. Int J Cardiol Heart Vasc 2024; 51:101379. [PMID: 38628295 PMCID: PMC11018635 DOI: 10.1016/j.ijcha.2024.101379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2023] [Revised: 02/09/2024] [Accepted: 02/27/2024] [Indexed: 04/19/2024]
Affiliation(s)
- Andrea Tedeschi
- Corresponding author at: Cardiology Department, Guglielmo da Saliceto Hospital, Piacenza, Italy.
| |
Collapse
|
2
|
Vidman S, Dion E, Tedeschi A. A Versatile Pipeline for High-fidelity Imaging and Analysis of Vascular Networks Across the Body. Bio Protoc 2024; 14:e4938. [PMID: 38405081 PMCID: PMC10883894 DOI: 10.21769/bioprotoc.4938] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2023] [Revised: 12/04/2023] [Accepted: 01/14/2024] [Indexed: 02/27/2024] Open
Abstract
Structural and functional changes in vascular networks play a vital role during development, causing or contributing to the pathophysiology of injury and disease. Current methods to trace and image the vasculature in laboratory settings have proven inconsistent, inaccurate, and labor intensive, lacking the inherent three-dimensional structure of vasculature. Here, we provide a robust and highly reproducible method to image and quantify changes in vascular networks down to the capillary level. The method combines vasculature tracing, tissue clearing, and three-dimensional imaging techniques with vessel segmentation using AI-based convolutional reconstruction to rapidly process large, unsectioned tissue specimens throughout the body with high fidelity. The practicality and scalability of our protocol offer application across various fields of biomedical sciences. Obviating the need for sectioning of samples, this method will expedite qualitative and quantitative analyses of vascular networks. Preparation of the fluorescent gel perfusate takes < 30 min per study. Transcardiac perfusion and vasculature tracing takes approximately 20 min, while dissection of tissue samples ranges from 5 to 15 min depending on the tissue of interest. The tissue clearing protocol takes approximately 24-48 h per whole-tissue sample. Lastly, three-dimensional imaging and analysis can be completed in one day. The entire procedure can be carried out by a competent graduate student or experienced technician. Key features • This robust and highly reproducible method allows users to image and quantify changes in vascular networks down to the capillary level. • Three-dimensional imaging techniques with vessel segmentation enable rapid processing of large, unsectioned tissue specimens throughout the body. • It takes approximately 2-3 days for sample preparation, three-dimensional imaging, and analysis. • The user-friendly pipeline can be completed by experienced and non-experienced users.
Collapse
Affiliation(s)
- Stephen Vidman
- Department of Neuroscience, Wexner Medical Center,
The Ohio State University, Columbus, OH, USA
- Neuroscience Graduate Program, The Ohio State
University, Columbus, OH, USA
| | - Elliot Dion
- Department of Neuroscience, Wexner Medical Center,
The Ohio State University, Columbus, OH, USA
| | - Andrea Tedeschi
- Department of Neuroscience, Wexner Medical Center,
The Ohio State University, Columbus, OH, USA
- Chronic Brain Injury Program, The Ohio State
University, Columbus, OH, USA
| |
Collapse
|
3
|
Tedeschi A, Ammirati E, Conti N, Dobrev D. Recent highlights on coronary artery disease from the International Journal of Cardiology Heart & Vasculature. Int J Cardiol Heart Vasc 2023; 49:101295. [PMID: 38035259 PMCID: PMC10682648 DOI: 10.1016/j.ijcha.2023.101295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2023]
Affiliation(s)
- Andrea Tedeschi
- De Gasperis Cardio Center, Niguarda Hospital, Milano, Italy
- Guglielmo da Saliceto Hospital, Piacenza, Italy
| | | | - Nicolina Conti
- De Gasperis Cardio Center, Niguarda Hospital, Milano, Italy
| | - Dobromir Dobrev
- Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany
- Department of Integrative Physiology, Baylor College of Medicine, Houston, USA
- Department of Medicine and Research Center, Montréal Heart Institute and Université de Montréal, Montréal, Canada
| |
Collapse
|
4
|
Asero R, Tedeschi A. Chronic spontaneous urticaria: from the hunt for causes and pathogenesis to the identification of different endotypes. Eur Ann Allergy Clin Immunol 2023; 55:253-260. [PMID: 37497632 DOI: 10.23822/eurannaci.1764-1489.307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/28/2023]
Abstract
Summary The hunt for the causes and pathogenic mechanisms involved in chronic spontaneous urticaria (CSU) has engaged clinicians and scientists for decades. Although not all aspects of the disease are defined, our knowledge has now improved to the point that we can consider CSU as an umbrella clinical phenotype under which several different endotypes probably exist. The present article will briefly summarize the fascinating history of the progress in our knowledge of this disease.
Collapse
Affiliation(s)
- R Asero
- Allergology Clinic, Clinica San Carlo, Paderno Dugnano, Milan, Italy
| | - A Tedeschi
- Department of Immunology Outpatient, UO General Medicine, Bolognini Hospital, ASST Bergamo Est, Seriate, Bergamo, Italy
| |
Collapse
|
5
|
Nithianandam P, Tzu-li L, Chen S, Yizhen J, Dong Y, Saul M, Tedeschi A, Wenjing S, Jinghua L. Flexible, Miniaturized Sensing Probes Inspired by Biofuel Cells for Monitoring Synaptically Released Glutamate in the Mouse Brain. Angew Chem Int Ed Engl 2023; 62:e202310245. [PMID: 37632702 PMCID: PMC10592105 DOI: 10.1002/anie.202310245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 08/20/2023] [Accepted: 08/24/2023] [Indexed: 08/28/2023]
Abstract
Chemical biomarkers in the central nervous system can provide valuable quantitative measures to gain insight into the etiology and pathogenesis of neurological diseases. Glutamate, one of the most important excitatory neurotransmitters in the brain, has been found to be upregulated in various neurological disorders, such as traumatic brain injury, Alzheimer's disease, stroke, epilepsy, chronic pain, and migraines. However, quantitatively monitoring glutamate release in situ has been challenging. This work presents a novel class of flexible, miniaturized probes inspired by biofuel cells for monitoring synaptically released glutamate in the nervous system. The resulting sensors, with dimensions as low as 50 by 50 μm, can detect real-time changes in glutamate within the biologically relevant concentration range. Experiments exploiting the hippocampal circuit in mice models demonstrate the capability of the sensors in monitoring glutamate release via electrical stimulation using acute brain slices. These advances could aid in basic neuroscience studies and translational engineering, as the sensors provide a diagnostic tool for neurological disorders. Additionally, adapting the biofuel cell design to other neurotransmitters can potentially enable the detailed study of the effect of neurotransmitter dysregulation on neuronal cell signaling pathways and revolutionize neuroscience.
Collapse
Affiliation(s)
- Prasad Nithianandam
- Department of Materials Science and Engineering, The Ohio State University, Columbus, OH 43210, USA
| | - Liu Tzu-li
- Department of Materials Science and Engineering, The Ohio State University, Columbus, OH 43210, USA
| | - Shulin Chen
- Department of Materials Science and Engineering, The Ohio State University, Columbus, OH 43210, USA
| | - Jia Yizhen
- Department of Materials Science and Engineering, The Ohio State University, Columbus, OH 43210, USA
| | - Yan Dong
- Department of Materials Science and Engineering, The Ohio State University, Columbus, OH 43210, USA
| | - Morgan Saul
- Department of Neuroscience, The Ohio State University College of Medicine, The Ohio State University, Columbus, OH 43210, USA
| | - Andrea Tedeschi
- Department of Neuroscience, The Ohio State University College of Medicine, Chronic Brain Injury Program, The Ohio State University, Columbus, OH 43210, USA
| | - Sun Wenjing
- Department of Neuroscience, The Ohio State University College of Medicine, Columbus, OH 43210, USA
| | - Li Jinghua
- Department of Materials Science and Engineering, Chronic Brain Injury Program, The Ohio State University, Columbus, OH 43210, USA
| |
Collapse
|
6
|
Gentile P, Masciocco G, Palazzini M, Tedeschi A, Ruzzenenti G, Conti N, D'Angelo L, Foti G, Perna E, Verde A, Ammirati E, Sinagra G, Oliva F, Garascia A. Intravenous continuous home inotropic therapy in advanced heart failure: Insights from an observational retrospective study. Eur J Intern Med 2023; 116:65-71. [PMID: 37393183 DOI: 10.1016/j.ejim.2023.06.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Revised: 05/23/2023] [Accepted: 06/12/2023] [Indexed: 07/03/2023]
Abstract
INTRODUCTION Intravenous inotropic support represents an important therapeutic option in advanced heart failure (HF) as bridge to heart transplantation, bridge to mechanical circulatory support, bridge to candidacy or as palliative therapy. Nevertheless, evidence regarding risks and benefits of its use is lacking. METHODS we conducted a retrospective single center study, analysing the effect of inotropic therapies in an outpatient cohort, evaluating the burden of hospitalizations, the improvement in quality of life, the incidence of adverse events and the evolution of organ damage. RESULTS twenty-seven patients with advanced HF were treated in our Day Hospital service from 2014 to 2021. Nine patients were treated as bridge to heart transplant while eighteen as palliation. Comparing data regarding the year before and after the beginning of inotropic infusion, we observed a reduction of hospitalization (46 vs 25, p<0,001), an improvement of natriuretic peptides, renal and hepatic function since the first month (p<0,001) and a better quality of life in 53% of the population treated. Two hospitalizations for arrhythmias and seven hospitalizations for catheter-related complications were registered. CONCLUSIONS in a selected population of advanced HF patients, continuous home inotropic infusion were able to reduce hospitalizations, improving end organ damage and quality of life. We provide a practical guidance on starting and maintaining home inotropic infusion while monitoring a challenging group of patients.
Collapse
Affiliation(s)
- Piero Gentile
- De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy
| | - Gabriella Masciocco
- De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy.
| | - Matteo Palazzini
- De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy
| | - Andrea Tedeschi
- De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy
| | - Giacomo Ruzzenenti
- De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy; Department of Health Sciences, University of Milano-Bicocca, Monza, Italy
| | - Nicolina Conti
- De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy
| | - Luciana D'Angelo
- De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy
| | - Grazia Foti
- De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy
| | - Enrico Perna
- De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy
| | - Alessandro Verde
- De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy
| | - Enrico Ammirati
- De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy
| | - Gianfranco Sinagra
- Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI) and University of Trieste, Trieste, Italy
| | - Fabrizio Oliva
- De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy
| | - Andrea Garascia
- De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy
| |
Collapse
|
7
|
Rodocker HI, Tedeschi A. Overcoming axon regeneration failure and psychopathology: how may gabapentinoids help boost CNS repair? Neural Regen Res 2023; 18:1703-1704. [PMID: 36751783 PMCID: PMC10154496 DOI: 10.4103/1673-5374.361668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Revised: 11/08/2022] [Accepted: 11/18/2022] [Indexed: 12/02/2022] Open
Affiliation(s)
- Haven I. Rodocker
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH, USA
| | - Andrea Tedeschi
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH, USA
- Chronic Brain Injury Program, The Ohio State University, Columbus, OH, USA
| |
Collapse
|
8
|
De Angelis E, Bochaton T, Ammirati E, Tedeschi A, Polito MV, Pieroni M, Merlo M, Gentile P, Van De Heyning CM, Bekelaar T, Cipriani A, Camilli M, Sanna T, Marra MP, Cabassi A, Piepoli MF, Sinagra G, Mewton N, Bonnefoy-Cudraz E, Ravera A, Hayek A. Pheochromocytoma-induced cardiogenic shock: A multicentre analysis of clinical profiles, management and outcomes. Int J Cardiol 2023; 383:82-88. [PMID: 37164293 DOI: 10.1016/j.ijcard.2023.05.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2023] [Revised: 05/03/2023] [Accepted: 05/05/2023] [Indexed: 05/12/2023]
Abstract
OBJECTIVE There is still uncertainty about the management of patients with pheochromocytoma-induced cardiogenic shock (PICS). This study aims to investigate the clinical presentation, management, and outcome of patients with PICS. METHODS We collected, retrospectively, the data of 18 patients without previously known pheochromocytoma admitted to 8 European hospitals with a diagnosis of PICS. RESULTS Among the 18 patients with a median age of 50 years (Q1-Q3: 40-61), 50% were men. The main clinical features at presentation were pulmonary congestion (83%) and cyclic fluctuation of hypertension peaks and hypotension (72%). Echocardiography showed a median left ventricular ejection fraction (LVEF) of 25% (Q1-Q3: 15-33.5) with an atypical- Takotsubo (TTS) pattern in 50%. Inotropes/vasopressors were started in all patients and temporary mechanical circulatory support (t-MCS) was required in 11 (61%) patients. All patients underwent surgical removal of the pheochromocytoma; 4 patients (22%) were operated on while under t-MCS. The median LVEF was estimated at 55% at discharge. Only one patient required heart transplantation (5.5%), and all patients were alive at a median follow-up of 679 days. CONCLUSIONS PICS should be suspected in case of a CS with severe cyclic blood pressure fluctuation and rapid hemodynamic deterioration, associated with increased inflammatory markers or in case of TTS progressing to CS, particularly if an atypical TTS echocardiographic pattern is revealed. T-MCS should be considered in the most severe cases. The main challenge is to stabilize the patient, with medical therapy or with t-MCS, since it remains a reversible cause of CS with a low mortality rate.
Collapse
Affiliation(s)
- Elena De Angelis
- Department of Cardiology and Intensive Care Unit, "S. Anna e SS. Madonna della Neve" Boscotrecase Hospital, Local Health Authority Naples 3 South, Naples, Italy; Intensive Cardiological Care Division, Louis Pradel Hospital, Hospices Civils de Lyon, Bron, France.
| | - Thomas Bochaton
- Intensive Cardiological Care Division, Louis Pradel Hospital, Hospices Civils de Lyon, Bron, France
| | - Enrico Ammirati
- "De Gasperis" Cardio Center, Niguarda Hospital, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | - Andrea Tedeschi
- "De Gasperis" Cardio Center, Niguarda Hospital, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; Cardiology Division, Parma University, Parma University Hospital, Parma, Italy
| | - Maria Vincenza Polito
- Cardiology Division, Cardiovascular and Thoracic Department, San Giovanni di Dio e Ruggi d'Aragona University Hospital, Salerno, Italy
| | - Maurizio Pieroni
- Cardiovascular Department, ASL8 Arezzo, "San Donato Hospital", Arezzo, Italy
| | - Marco Merlo
- Cardiothoracovascular Department, Azienda Sanitaria Universitaria "Giuliano Isontina" (ASUGI), University of Trieste, Trieste, Italy
| | - Piero Gentile
- "De Gasperis" Cardio Center, Niguarda Hospital, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | | | - Thalia Bekelaar
- Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium
| | - Alberto Cipriani
- Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua Medical School, Padua, Italy
| | - Massimiliano Camilli
- Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy
| | - Tommaso Sanna
- Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy
| | - Martina Perazzolo Marra
- Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua Medical School, Padua, Italy
| | - Aderville Cabassi
- Cardiorenal and Hypertension Research Unit, Physiopathology Unit, Clinica Medica Generale e Terapia Medica, Department of Medicine and Surgery (DIMEC), University of Parma, Parma, Italy
| | - Massimo F Piepoli
- Cardiology Department, Guglielmo da Saliceto Hospital of Piacenza, Piacenza, Italy
| | - Gianfranco Sinagra
- Cardiothoracovascular Department, Azienda Sanitaria Universitaria "Giuliano Isontina" (ASUGI), University of Trieste, Trieste, Italy
| | - Nathan Mewton
- Clinical Investigation Centre and Heart Failure Department, Hôpital Cardiovasculaire Louis Pradel, Inserm 1407, France
| | - Eric Bonnefoy-Cudraz
- Intensive Cardiological Care Division, Louis Pradel Hospital, Hospices Civils de Lyon, Bron, France
| | - Amelia Ravera
- Intensive Cardiac Care Unit, Cardiology Division, Cardiovascular and Thoracic Department, San Giovanni di Dio e Ruggi d'Aragona University Hospital, Salerno, Italy
| | - Ahmad Hayek
- Intensive Cardiological Care Division, Louis Pradel Hospital, Hospices Civils de Lyon, Bron, France; Interventional Department, Montreal heart Institute, Quebec, Canada
| |
Collapse
|
9
|
Garascia A, Palazzini M, Tedeschi A, Sacco A, Oliva F, Gentile P. Advanced heart failure: from definitions to therapeutic options. Eur Heart J Suppl 2023; 25:C283-C291. [PMID: 37125285 PMCID: PMC10132575 DOI: 10.1093/eurheartjsupp/suad028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
Advanced heart failure (AHF) represents an ominous stage of heart failure (HF), where the expected prognosis remains poor regardless of the improvement in medical knowledge. In this review, we summarize the definition, prognosis, physiopathology, and clinical/therapeutic management of the disease, focusing on the fast and timely referral of the patient to the AHF facilities. We provide an insight of the diagnostic and therapeutic 'work up' performed in an Italian AHF hub, implying a deep phenotypical patients characterization in order to evaluate candidacy to the therapeutic gold standards as heart transplantation (HTx) and left ventricular assist device (LVAD).
Collapse
Affiliation(s)
- Andrea Garascia
- De Gasperis Cardio Center, Ospedale Niguarda, Piazza Ospedale Maggiore 3, Milano, Italia
| | - Matteo Palazzini
- De Gasperis Cardio Center, Ospedale Niguarda, Piazza Ospedale Maggiore 3, Milano, Italia
| | - Andrea Tedeschi
- De Gasperis Cardio Center, Ospedale Niguarda, Piazza Ospedale Maggiore 3, Milano, Italia
| | - Alice Sacco
- De Gasperis Cardio Center, Ospedale Niguarda, Piazza Ospedale Maggiore 3, Milano, Italia
| | - Fabrizio Oliva
- De Gasperis Cardio Center, Ospedale Niguarda, Piazza Ospedale Maggiore 3, Milano, Italia
| | - Piero Gentile
- Corresponding author. Tel: +39 02 6444 7791, Fax: +39 02 6444 2566,
| |
Collapse
|
10
|
Tedeschi A, Camilli M, Ammirati E, Gentile P, Palazzini M, Conti N, Verde A, Masciocco G, Foti G, Giannattasio C, Garascia A. Immune checkpoint inhibitor-associated myocarditis: from pathophysiology to rechallenge of therapy - a narrative review. Future Cardiol 2023; 19:91-103. [PMID: 37078438 DOI: 10.2217/fca-2022-0120] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/21/2023] Open
Abstract
Even if immune checkpoint inhibitors have revolutionized the landscape of cancer therapy, their use may be complicated by immune-related adverse events. Among these, myocarditis is the most severe complication. The clinical suspicion often arises after clinical symptoms onset and increase in cardiac biomarkers or electrocardiographic manifestations. Echocardiography and cardiac magnetic resonance imaging are recommended for each patient. However, since they may be misleadingly normal, endomyocardial biopsy remains the gold standard for establishing the diagnosis. Until now, treatment has been based on glucocorticoids even if increasing interest has risen in other immunosuppressive agents. Although myocarditis currently imposes immunotherapy discontinuation, case reports have suggested a safety rechallenge in low-grade myocarditis paving the way for further studies to respond to this unmet clinical need.
Collapse
Affiliation(s)
- Andrea Tedeschi
- "De Gasperis" Cardio Center, Niguarda Hospital, ASST Grande Ospedale Metropolitano Niguarda, Milan, 20162, Italy
| | - Massimiliano Camilli
- Department of Cardiovascular & Thoracic Sciences, Catholic University of the Sacred Heart, Rome, 00168, Italy
| | - Enrico Ammirati
- "De Gasperis" Cardio Center, Niguarda Hospital, ASST Grande Ospedale Metropolitano Niguarda, Milan, 20162, Italy
| | - Piero Gentile
- "De Gasperis" Cardio Center, Niguarda Hospital, ASST Grande Ospedale Metropolitano Niguarda, Milan, 20162, Italy
| | - Matteo Palazzini
- "De Gasperis" Cardio Center, Niguarda Hospital, ASST Grande Ospedale Metropolitano Niguarda, Milan, 20162, Italy
| | - Nicolina Conti
- "De Gasperis" Cardio Center, Niguarda Hospital, ASST Grande Ospedale Metropolitano Niguarda, Milan, 20162, Italy
| | - Alessandro Verde
- "De Gasperis" Cardio Center, Niguarda Hospital, ASST Grande Ospedale Metropolitano Niguarda, Milan, 20162, Italy
| | - Gabriella Masciocco
- "De Gasperis" Cardio Center, Niguarda Hospital, ASST Grande Ospedale Metropolitano Niguarda, Milan, 20162, Italy
| | - Grazia Foti
- "De Gasperis" Cardio Center, Niguarda Hospital, ASST Grande Ospedale Metropolitano Niguarda, Milan, 20162, Italy
| | - Cristina Giannattasio
- "De Gasperis" Cardio Center, Niguarda Hospital, ASST Grande Ospedale Metropolitano Niguarda, Milan, 20162, Italy
| | - Andrea Garascia
- "De Gasperis" Cardio Center, Niguarda Hospital, ASST Grande Ospedale Metropolitano Niguarda, Milan, 20162, Italy
| |
Collapse
|
11
|
D'Sa S, Matous JV, Advani R, Buske C, Castillo JJ, Gatt M, Kapoor P, Kersten MJ, Leblond V, Leiba M, Palomba ML, Paludo J, Qiu L, Sarosiek S, Shadman M, Talaulikar D, Tam CS, Tedeschi A, Thomas SK, Tohidi-Esfahani I, Trotman J, Varettoni M, Vos J, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP, Kastritis E. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients. Semin Hematol 2023; 60:80-89. [PMID: 37147252 DOI: 10.1053/j.seminhematol.2023.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Accepted: 03/09/2023] [Indexed: 03/29/2023]
Abstract
The consensus panel 2 (CP2) of the 11th International Workshop on Waldenström's macroglobulinemia (IWWM-11) has reviewed and incorporated current data to update the recommendations for treatment approaches in patients with relapsed or refractory WM (RRWM). The key recommendations from IWWM-11 CP2 include: (1) Chemoimmunotherapy (CIT) and/or a covalent Bruton tyrosine kinase (cBTKi) strategies are important options; their use should reflect the prior upfront strategy and are subject to their availability. (2) In selecting treatment, biological age, co-morbidities and fitness are important; nature of relapse, disease phenotype and WM-related complications, patient preferences and hematopoietic reserve are also critical factors while the composition of the BM disease and mutational status (MYD88, CXCR4, TP53) should also be noted. (3) The trigger for initiating treatment in RRWM should utilize knowledge of patients' prior disease characteristics to avoid unnecessary delays. (4) Risk factors for cBTKi related toxicities (cardiovascular dysfunction, bleeding risk and concurrent medication) should be addressed when choosing cBTKi. Mutational status (MYD88, CXCR4) may influence the cBTKi efficacy, and the role of TP53 disruptions requires further study) in the event of cBTKi failure dose intensity could be up titrated subject to toxicities. Options after BTKi failure include CIT with a non-cross-reactive regimen to one previously used CIT, addition of anti-CD20 antibody to BTKi, switching to a newer cBTKi or non-covalent BTKi, proteasome inhibitors, BCL-2 inhibitors, and new anti-CD20 combinations are additional options. Clinical trial participation should be encouraged for all patients with RRWM.
Collapse
Affiliation(s)
- S D'Sa
- UCLH Centre for Waldenström Macroglobulinaemia and Related Conditions, University College London Hospitals NHS Foundation Trust, London, UK.
| | - J V Matous
- Colorado Blood Cancer Institute, Sarah Cannon Research Institute, Denver, CO
| | - R Advani
- Stanford University Medical Center, Stanford, CA
| | - C Buske
- University Hospital Ulm, Ulm, Germany
| | - J J Castillo
- Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - M Gatt
- Hadassah University Medical Center, Jerusalem, Israel
| | | | - M J Kersten
- Amsterdam UMC, University of Amsterdam, Department of Hematology, Cancer Center Amsterdam/LYMMCARE, Amsterdam, Netherlands
| | - V Leblond
- Groupe Hospitalier Pitié-Salpêtrière, Sorbonne University, Paris, France
| | - M Leiba
- Assuta Ashdod University Hospital; Faculty of Health Science, Ben-Gurion University of the Negev, Negev, Israel Memorial Sloan Kettering Cancer Center, New York, NY
| | - M L Palomba
- Memorial Sloan Kettering Cancer Center, New York NY US
| | | | - L Qiu
- National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - S Sarosiek
- Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
| | | | - D Talaulikar
- ANU College of Health and Medicine, Canberra, Australia
| | - C S Tam
- Alfred Health, Monash University, Melbourne, Australia
| | - A Tedeschi
- A. O. Ospedale Niguarda Ca' Granda, Milan, Italy
| | - S K Thomas
- University of Texas, MD Anderson Cancer Center, Houston TX USA
| | - I Tohidi-Esfahani
- Concord Repatriation General Hospital, University of Sydney, Sydney, Australia
| | - J Trotman
- Concord Repatriation General Hospital, University of Sydney, Sydney, Australia
| | - M Varettoni
- Division of Hematology, Fondazione iRCCS Policlinico, San Matteo, Italy
| | - Jmi Vos
- Amsterdam UMC, University of Amsterdam, Department of Hematology, Cancer Center Amsterdam/LYMMCARE, Amsterdam, Netherlands
| | - R Garcia-Sanz
- Hematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca, CIBERONC and Center for Cancer Research-IBMCC (University of Salamanca-CSIC), Salamanca, Spain
| | - J San-Miguel
- Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red Cáncer, Pamplona, Spain
| | - M A Dimopoulos
- Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
| | - S P Treon
- Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - E Kastritis
- Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
| |
Collapse
|
12
|
Asero R, Pinter E, Tedeschi A. 35 years of autologous serum skin test in chronic spontaneous urticaria: what we know and what we do not know. Eur Ann Allergy Clin Immunol 2023; 55:4-8. [PMID: 34904801 DOI: 10.23822/eurannaci.1764-1489.238] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Summary The autologous serum skin test (ASST) has been used in patients with chronic spontaneous urticaria (CSU) as a means to detect an autoreactivity state for thirty-five years now. Nonetheless, several aspects of this old diagnostic test are still insufficiently defined. Particularly, the nature of the factor(s) responsible for the appearance of the wheal-and-flare skin reaction is still poorly characterized. This article will review our current knowledge about the clinical significance of the ASST and the factors possibly associated with the occurrence of the skin reaction following the intradermal administration of autologous serum that are known so far.
Collapse
Affiliation(s)
- R Asero
- Allergology Clinic, Clinica San Carlo, Paderno Dugnano, Milan, Italy
| | - E Pinter
- UOC Internal Medicine and Clinical Immunology, University of Rome La Sapienza, Policlinico Umberto I, Rome, Italy
| | - A Tedeschi
- Department of Immunology Outpatient, UO General Medicine, Bolognini Hospital, ASST Bergamo Est, Seriate, Bergamo, Italy
| |
Collapse
|
13
|
Gentile P, Palazzini M, Tedeschi A, Ammirati E, Perna E, Verde A, D´angelo L, Masciocco G, Garascia A. 139 INTRAVENOUS CONTINUOUS HOME INOTROPIC THERAPY IN ADVANCED HEART FAILURE - RESULTS AND PRACTICAL GUIDELINES. Eur Heart J Suppl 2022. [DOI: 10.1093/eurheartjsupp/suac121.474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Abstract
Background
no firm data exist regarding continuous intravenous inotropic infusion in outpatients with advanced heart failure (AHF).
Methods
We reviewed medical records of all inotrope dependent patients discharged from our institution on continuous home inotropes infusion for AHF after a hospitalization between 2014 and 2021. Indications for inotropic agents included bridge to transplant (BTT) or to candidacy (BTC) strategies or palliative care. We compared the number of hospitalizations the year before and the year after beginning the inotrope continuous infusion, assessing the main hospital diagnosis and the duration of hospital recovery in days, through hospital charts revision. Moreover, we used a linkert 7 item scale to assess quality of life (QoL) and, using peripheral blood sample, we esteemed the end organ damage trend evaluating NTproBNP, creatinine, blood urea nitrogen (BUN) and bilirubin.
Results
From 2014 to 2021, 27 patients (Median age 56 years (Q1-Q3 50-63 years), 74% male and 26% female) were dismissed with continuous inotrope infusion from our institution. The total number of days of hospital stay was 1591 the year before beginning inotropic support (average 58.93 ± 38.70 for patient), significantly different if compared with the post inotropes period (average 22,19 ± 36,84 days for patients, IC 95% 17,488-55,994 p < 0,001). Moreover, the number of hospitalizations per patient fell from 1.93 ± 0.997 to 0,93 ± 0,958 (IC 95% 0,522- 1,478, p < 0,001). After 6 months, 53% of the patients experienced an improvement in quality of life. Regarding end organ damage, while creatinine and BUN showed a significant reduction in the first month, with a trend to stability in the following period, bilirubin and NTproBNP significantly trended to reduction during the 6 month of monitoring.
Conclusions
In a real world population of contemporary AHF, continuous inotropes home infusion documented an improvement in hospitalization, QoL and end organ damage. We offer a practical guideline on initiation, selection and maintenance of chronic inotrope therapy in a population of challenging patients.
Collapse
Affiliation(s)
- Piero Gentile
- De Gasperis Cardio Center, Niguarda Hospital , Milano , Italy
| | | | - Andrea Tedeschi
- De Gasperis Cardio Center, Niguarda Hospital , Milano , Italy
| | - Enrico Ammirati
- De Gasperis Cardio Center, Niguarda Hospital , Milano , Italy
| | - Enrico Perna
- De Gasperis Cardio Center, Niguarda Hospital , Milano , Italy
| | | | | | | | - Andrea Garascia
- De Gasperis Cardio Center, Niguarda Hospital , Milano , Italy
| |
Collapse
|
14
|
Angelis ED, Bochaton T, Ammirati E, Tedeschi A, Polito MV, Pieroni M, Merlo M, Van De Heyning CM, Cipriani A, Camilli M, Sanna T, Cabassi A, Piepoli MF, Sinagra G, Bonnefoy-cudraz E, Ravera A, Hayek A. 108 PHEOCHROMOCYTOMA-INDUCED CARDIOGENIC SHOCK: A MULTICENTRE ANALYSIS OF CLINICAL PROFILES, MANAGEMENT AND OUTCOMES. Eur Heart J Suppl 2022. [DOI: 10.1093/eurheartjsupp/suac121.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Abstract
Aims
There is still uncertainty on the management of patients with pheochromocytoma-induced CS (PICS), as only a few clinical cases have been reported. The aim of this study is to investigate the clinical presentation, management, and outcome of patients with PICS.
Methods
We collected retrospectively 18 patients without previously known pheochromocytoma with histologically proven PICS admitted to 8 European hospitals.
Results
Among the 18 patients with a mean age of 50 years, 50% were men. The main clinical features at presentation were pulmonary congestion (83%) and cyclic fluctuation of hypertension crises and hypotension (72%). On echocardiography, mean left ventricular ejection fraction (LVEF) was 25% with an atypical-Takotsubo pattern (basal/midventricular) in 50%. Laboratory exams showed increased inflammatory markers, in particular, the mean white blood count was 21.9*109/L. Inotropes/vasopressors were started in all patients and a temporary mechanical circulatory support (t-MCS) was required in 11 (61.1%) patients. All patients underwent surgical removal of the pheochromocytoma but 4 (22.2%) on t-MCS. Echocardiogram (16/17 patients) revealed a mean LVEF of 55% at discharge. Only one patient required heart transplantation (5.5%), and all patients were alive at a median follow-up of 679 days.
Conclusions
In patients with PICS, characteristically, an atypical Takotsubo pattern was observed in almost half of the cases. Although the use of exogenous catecholamine can be perceived as deleterious, we showed a fairly good mid-term prognosis with rapid improvement of LVEF in most, even if adrenalectomy often occurred on t-MCS.
Collapse
Affiliation(s)
- Elena De Angelis
- Department Of Cardiology And Intensive Cardiac Care Unit ”S.Anna E Ss. Madonna Della Neve” Boscotrecase Hospital , Naples , Italy
| | - Thomas Bochaton
- Intensive Cardiological Care Division, Louis Pradel Hospital , Hospices Civils De Lyon, Bron , France
| | - Enrico Ammirati
- ”De Gasperis” Cardio Center, Niguarda Hospital , Asst Grane Ospedale Metropolitano Niguarda, Milan , Italy
| | - Andrea Tedeschi
- ”De Gasperis” Cardio Center, Niguarda Hospital , Asst Grane Ospedale Metropolitano Niguarda, Milan , Italy
- Cardiology Division, Parma University Hospital , Parma , Italy
| | - Maria Vincenza Polito
- Cardiology Division, Cardiovascular And Thoracic Department, San Giovanni Di Dio E Ruggi D’aragona University Hospital , Salerno , Italy
| | - Maurizio Pieroni
- Cardiovascular Department Asl8 Arezzo San Donato Hospital , Parma , Italy
| | - Marco Merlo
- Cardiothoracovascular Department, Azienda Sanitaria Universitaria ”Giuliano Isontina”, University Of Trieste , Italy
| | | | - Alberto Cipriani
- Department Of Cardio-Thoraco-Vascular Sciences And Public Health, University Of Padua Medical School , Padua , Italy
| | - Massimiliano Camilli
- Department Of Cardiovascular Medicine, Fondazione Policlinico Universitario A.Gemelli Irccs,Rome , Italy
| | - Tommaso Sanna
- Department Of Cardiovascular Medicine, Fondazione Policlinico Universitario A.Gemelli Irccs,Rome , Italy
| | - Aderville Cabassi
- Cardiorenal And Hypertension Research Unit, Physiopathology Unit, Clinica Medica Generale E Terapia Medica, Department Of Medicine And Surgery, University Of Parma , Italy
| | - Massimo F Piepoli
- Cardiology Department, Guglielmo Da Saliceto Hospital Of Piacenza , Italy
| | - Gianfranco Sinagra
- Cardiothoracovascular Department, Azienda Sanitaria Universitaria ”Giuliano Isontina”, University Of Trieste , Italy
| | - Eric Bonnefoy-cudraz
- Intensive Cardiological Care Division, Louis Pradel Hospital , Hospices Civils De Lyon, Bron , France
| | - Amelia Ravera
- Cardiology Division, Cardiovascular And Thoracic Department, San Giovanni Di Dio E Ruggi D’aragona University Hospital , Salerno , Italy
| | - Ahmad Hayek
- Intensive Cardiological Care Division, Louis Pradel Hospital , Hospices Civils De Lyon, Bron , France
- Interventional Department, Montreal Heart Institute , Quebec , Canada
| |
Collapse
|
15
|
Tedeschi A, Larson MJE, Zouridakis A, Mo L, Bordbar A, Myers JM, Qin HY, Rodocker HI, Fan F, Lannutti JJ, McElroy CA, Nimjee SM, Peng J, Arnold WD, Moon LDF, Sun W. Harnessing cortical plasticity via gabapentinoid administration promotes recovery after stroke. Brain 2022; 145:2378-2393. [PMID: 35905466 PMCID: PMC9890504 DOI: 10.1093/brain/awac103] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2021] [Revised: 02/18/2022] [Accepted: 02/26/2022] [Indexed: 02/04/2023] Open
Abstract
Stroke causes devastating sensory-motor deficits and long-term disability due to disruption of descending motor pathways. Restoration of these functions enables independent living and therefore represents a high priority for those afflicted by stroke. Here, we report that daily administration of gabapentin, a clinically approved drug already used to treat various neurological disorders, promotes structural and functional plasticity of the corticospinal pathway after photothrombotic cortical stroke in adult mice. We found that gabapentin administration had no effects on vascular occlusion, haemodynamic changes nor survival of corticospinal neurons within the ipsilateral sensory-motor cortex in the acute stages of stroke. Instead, using a combination of tract tracing, electrical stimulation and functional connectivity mapping, we demonstrated that corticospinal axons originating from the contralateral side of the brain in mice administered gabapentin extend numerous collaterals, form new synaptic contacts and better integrate within spinal circuits that control forelimb muscles. Not only does gabapentin daily administration promote neuroplasticity, but it also dampens maladaptive plasticity by reducing the excitability of spinal motor circuitry. In turn, mice administered gabapentin starting 1 h or 1 day after stroke recovered skilled upper extremity function. Functional recovery persists even after stopping the treatment at 6 weeks following a stroke. Finally, chemogenetic silencing of cortical projections originating from the contralateral side of the brain transiently abrogated recovery in mice administered gabapentin, further supporting the conclusion that gabapentin-dependent reorganization of spared cortical pathways drives functional recovery after stroke. These observations highlight the strong potential for repurposing gabapentinoids as a promising treatment strategy for stroke repair.
Collapse
Affiliation(s)
- Andrea Tedeschi
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA
- Discovery Theme on Chronic Brain Injury, The Ohio State University, Columbus, OH 43210, USA
| | - Molly J E Larson
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA
| | - Antonia Zouridakis
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA
| | - Lujia Mo
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA
| | - Arman Bordbar
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA
| | - Julia M Myers
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA
| | - Hannah Y Qin
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA
| | - Haven I Rodocker
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA
| | - Fan Fan
- Department of Materials Science and Engineering, The Ohio State University, Columbus, OH 43210, USA
| | - John J Lannutti
- Discovery Theme on Chronic Brain Injury, The Ohio State University, Columbus, OH 43210, USA
- Department of Materials Science and Engineering, The Ohio State University, Columbus, OH 43210, USA
| | - Craig A McElroy
- Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, Columbus, OH 43210, USA
| | - Shahid M Nimjee
- Discovery Theme on Chronic Brain Injury, The Ohio State University, Columbus, OH 43210, USA
- Department of Neurosurgery, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA
| | - Juan Peng
- Center for Biostatistics and Bioinformatics, The Ohio State University, Columbus, OH 43210, USA
| | - W David Arnold
- Division of Neuromuscular Diseases, Department of Neurology, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA
| | - Lawrence D F Moon
- Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, London, UK
| | - Wenjing Sun
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA
| |
Collapse
|
16
|
Rodocker HI, Bordbar A, Larson MJE, Biltz RG, Wangler L, Fadda P, Godbout JP, Tedeschi A. Breaking Mental Barriers Promotes Recovery After Spinal Cord Injury. Front Mol Neurosci 2022; 15:868563. [PMID: 35875670 PMCID: PMC9301320 DOI: 10.3389/fnmol.2022.868563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Accepted: 06/14/2022] [Indexed: 11/23/2022] Open
Abstract
Functional recovery after spinal cord injury (SCI) often proves difficult as physical and mental barriers bar survivors from enacting their designated rehabilitation programs. We recently demonstrated that adult mice administered gabapentinoids, clinically approved drugs prescribed to mitigate chronic neuropathic pain, recovered upper extremity function following cervical SCI. Given that rehabilitative training enhances neuronal plasticity and promotes motor recovery, we hypothesized that the combination of an aerobic-based rehabilitation regimen like treadmill training with gabapentin (GBP) administration will maximize recovery in SCI mice by strengthening synaptic connections along the sensorimotor axis. Whereas mice administered GBP recovered forelimb functions over the course of weeks and months following SCI, no additive forelimb recovery as the result of voluntary treadmill training was noted in these mice. To our surprise, we also failed to find an additive effect in mice administered vehicle. As motivation is crucial in rehabilitation interventions, we scored active engagement toward the rehabilitation protocol and found that mice administered GBP were consistently participating in the rehabilitation program. In contrast, mice administered vehicle exhibited a steep decline in participation, especially at chronic time points. Whereas neuroinflammatory gene expression profiles were comparable between experimental conditions, we discovered that mice administered GBP had increased hippocampal neurogenesis and exhibited less anxiety-like behavior after SCI. We also found that an external, social motivator effectively rescues participation in mice administered vehicle and promotes forelimb recovery after chronic SCI. Thus, not only does a clinically relevant treatment strategy preclude the deterioration of mental health after chronic SCI, but group intervention strategies may prove to be physically and emotionally beneficial for SCI individuals.
Collapse
Affiliation(s)
- Haven I. Rodocker
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH, United States
| | - Arman Bordbar
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH, United States
| | - Molly J. E. Larson
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH, United States
| | - Rebecca G. Biltz
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH, United States
- Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, United States
| | - Lynde Wangler
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH, United States
- Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, United States
| | - Paolo Fadda
- Department of Cancer Biology, The Ohio State University, Columbus, OH, United States
| | - Jonathan P. Godbout
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH, United States
- Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, United States
- Chronic Brain Injury Program, The Ohio State University, Columbus, OH, United States
| | - Andrea Tedeschi
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH, United States
- Chronic Brain Injury Program, The Ohio State University, Columbus, OH, United States
- *Correspondence: Andrea Tedeschi
| |
Collapse
|
17
|
Mauro FR, Giannarelli D, Galluzzo C, Visentin A, Frustaci AM, Sportoletti P, Vitale C, Reda G, Gentile M, Levato L, Murru R, Armiento D, Ielo C, Maglione R, Crisanti E, Cipiciani A, Mattiello V, Gianfelici V, Barabino L, Amici R, Coscia M, Tedeschi A, Trentin L, Baroncelli S. P660: SEROLOGIC RESPONSE TO THE SECOND AND THIRD DOSE OF THE SARS-COV-2 VACCINE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A PROSPECTIVE, CENTRALIZED, MULTICENTER STUDY. Hemasphere 2022. [DOI: 10.1097/01.hs9.0000845524.05971.e8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
18
|
Tedeschi A, Camilli M, Ianni U, Tavecchia G, Palazzini M, Cartella I, Gentile P, Quattrocchi G, Maria Spanò F, Cipriani M, Garascia A, Ammirati E. Takotsubo syndrome after BNT162b2 mRNA Covid-19 vaccine: Emotional or causative relationship with vaccination? IJC Heart & Vasculature 2022; 40:101002. [PMID: 35340274 PMCID: PMC8934733 DOI: 10.1016/j.ijcha.2022.101002] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2022] [Revised: 03/07/2022] [Accepted: 03/08/2022] [Indexed: 01/24/2023]
|
19
|
Eltobgy MM, Zani A, Kenney AD, Estfanous S, Kim E, Badr A, Carafice C, Daily K, Whitham O, Pietrzak M, Webb A, Kawahara J, Eddy AC, Denz P, Lu M, Mahesh KC, Peeples ME, Li J, Zhu J, Que J, Robinson R, Mejia OR, Rayner RE, Hall-Stoodley L, Seveau S, Gavrilin MA, Zhang X, Thomas J, Kohlmeier JE, Suthar MS, Oltz E, Tedeschi A, Robledo-Avila FH, Partida-Sanchez S, Hemann EA, Abdelrazik E, Forero A, Nimjee SM, Boyaka PN, Cormet-Boyaka E, Yount JS, Amer AO. Caspase-4/11 exacerbates disease severity in SARS-CoV-2 infection by promoting inflammation and immunothrombosis. Proc Natl Acad Sci U S A 2022; 119:e2202012119. [PMID: 35588457 PMCID: PMC9173818 DOI: 10.1073/pnas.2202012119] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Accepted: 04/11/2022] [Indexed: 02/07/2023] Open
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2) is a worldwide health concern, and new treatment strategies are needed. Targeting inflammatory innate immunity pathways holds therapeutic promise, but effective molecular targets remain elusive. Here, we show that human caspase-4 (CASP4) and its mouse homolog, caspase-11 (CASP11), are up-regulated in SARS–CoV-2 infections and that CASP4 expression correlates with severity of SARS–CoV-2 infection in humans. SARS–CoV-2–infected Casp11−/− mice were protected from severe weight loss and lung pathology, including blood vessel damage, compared to wild-type (WT) mice and mice lacking the caspase downstream effector gasdermin-D (Gsdmd−/−). Notably, viral titers were similar regardless of CASP11 knockout. Global transcriptomics of SARS–CoV-2–infected WT, Casp11−/−, and Gsdmd−/− lungs identified restrained expression of inflammatory molecules and altered neutrophil gene signatures in Casp11−/− mice. We confirmed that protein levels of inflammatory mediators interleukin (IL)-1β, IL-6, and CXCL1, as well as neutrophil functions, were reduced in Casp11−/− lungs. Additionally, Casp11−/− lungs accumulated less von Willebrand factor, a marker for endothelial damage, but expressed more Kruppel-Like Factor 2, a transcription factor that maintains vascular integrity. Overall, our results demonstrate that CASP4/11 promotes detrimental SARS–CoV-2–induced inflammation and coagulopathy, largely independently of GSDMD, identifying CASP4/11 as a promising drug target for treatment and prevention of severe COVID-19.
Collapse
Affiliation(s)
- Mostafa M. Eltobgy
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Neuroscience graduate program, The Ohio State University, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| | - Ashley Zani
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| | - Adam D. Kenney
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| | - Shady Estfanous
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
- Faculty of Pharmacy, Helwan University, Cairo,11731 Egypt
| | - Eunsoo Kim
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
- Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210
| | - Asmaa Badr
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| | - Cierra Carafice
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| | - Kylene Daily
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| | - Owen Whitham
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| | - Maciej Pietrzak
- Department of Biomedical Informatics, The Ohio State University, Columbus, OH 43210
| | - Amy Webb
- Department of Biomedical Informatics, The Ohio State University, Columbus, OH 43210
| | - Jeffrey Kawahara
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| | - Adrian C. Eddy
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| | - Parker Denz
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| | - Mijia Lu
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
- Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210
| | - KC Mahesh
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
- Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH 43205
| | - Mark E. Peeples
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
- Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH 43205
| | - Jianrong Li
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
- Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210
| | - Jian Zhu
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
- Department of Pathology, The Ohio State University, Columbus, OH 43210
| | - Jianwen Que
- Division of Digestive and Liver Diseases and Center for Human Development, Department of Medicine, Columbia University, New York, NY 10027
| | - Richard Robinson
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| | - Oscar Rosas Mejia
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| | - Rachael E. Rayner
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
- Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210
| | - Luanne Hall-Stoodley
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| | - Stephanie Seveau
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| | - Mikhail A. Gavrilin
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| | - Xiaoli Zhang
- Department of Biomedical Informatics, The Ohio State University, Columbus, OH 43210
| | - Jeronay Thomas
- Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322
| | - Jacob E. Kohlmeier
- Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322
| | - Mehul S. Suthar
- Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322
- Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30322
| | - Eugene Oltz
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
| | - Andrea Tedeschi
- Department of Neuroscience, Chronic Brain Injury Discovery Theme, The Ohio State University, Columbus, OH 43210
| | - Frank H. Robledo-Avila
- Center for Microbial Pathogenesis, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH 43205
| | - Santiago Partida-Sanchez
- Center for Microbial Pathogenesis, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH 43205
| | - Emily A. Hemann
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| | - Eman Abdelrazik
- Center for Informatics Science, Nile University, Giza, 12525, Egypt
| | - Adriana Forero
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| | - Shahid M. Nimjee
- Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210
| | - Prosper N. Boyaka
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
- Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210
| | - Estelle Cormet-Boyaka
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
- Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210
| | - Jacob S. Yount
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| | - Amal O. Amer
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210
| |
Collapse
|
20
|
De Angelis E, Ravera A, Ammirati E, Tedeschi A, Polito M, Pieroni M, Gentile P, Merlo M, Van De Heyning C, Bekelaarh T, Cipriani A, Camilli M, Sanna T, Sinagra G, Bonnefoy–cudraz E, Bochaton T, Hayek A, Aloia A. C75 PHEOCHROMOCYTOMA–INDUCED CARDIOGENIC SHOCK: A MULTICENTER ANALYSIS OF CLINICAL PROFILES, MANAGEMENT AND OUTCOMES. Eur Heart J Suppl 2022. [DOI: 10.1093/eurheartj/suac011.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Background
Pheochromocytoma is a rare neuroendocrine tumor that arises from the adrenal gland and overproduces catecholamines; it is an infrequent cause of cardiogenic shock (CS). Several case reports have investigated pheochromocytoma–induced CS, but larger studies have not yet been carried out.
Objectives
Our work aims to describe a multicenter experience in the diagnosis and management of patients with pheochromocytoma–induced CS, and to raise awareness around this rare condition. Methods: We enrolled all patients with a diagnosis of pheochromocytoma–induced CS admitted to the intensive care units of 8 European referral Hospitals.
Results
Among the 17 patients (47% males, mean age 49,5 years), we found that pulmonary congestion was the mostly represented clinical feature (82%). The most represented echocardiographic left ventricle (LV) pattern was the reverse Takotsubo (TTS) pattern with apical hyperkinesis associated with basal– to mid–ventricular hypokinesis (47%). Elevated systemic vascular resistances (SVR) were observed. Endomyocardial biopsy of the LV was performed in one patient showing contraction band necrosis, oedema and inflammatory reaction. 76% of patients were treated with dobutamine, 70% needed noradrenaline, 29% adrenaline, 23.5% were treated with levosimendan and 17% with milrinone. Mechanical circulatory support devices (MCS) were necessary for 65% of patients. All patients benefited from pheochromocytoma’s surgical excision, with 4 patients operated on while under ECLS. All patients recovered, excepted one (presenting a severe left ventricular dilatation at admission) who required cardiac transplantation.
Conclusion
Pheochromocytoma is an infrequent cause of CS, with most often a TTS–like presentation. It should be suspected in case of a CS with high initial SVR and rapid deterioration. MCS must be considered in the most severe cases. The main challenge is to stabilize the patient, mostly with MCS, since it remains a reversible cause of CS with a low mortality rate. Adrenalectomy can safely be performed even when the patient is under MCS.
Collapse
Affiliation(s)
- E De Angelis
- PRESIDIO OSPEDALIERO SAN LUCA, VALLO DELLA LUCANIA; AZIENDA OSPEDALIERA UNIVERSITARIA “SAN GIOVANNI DI DIO E RUGGI D‘ARAGONA”, SALERNO; DE GASPERIS CARDIO CENTER GRANDE OSPEDALE METROPOLITANO NIGUARDA, MILANO; OSPEDALE SAN DONATO, AREZZO; AZIENDA SANITARIA UNIVERSITARIA “GIULIANO ISONTINA”, UNIVERSITÀ DI TRIESTE, TRIESTE; OSPEDALE UNIVERSITARIO DI ANVERSA, ANVERSA; AZIENDA OSPEDALIERA UNIVERSITAR
| | - A Ravera
- PRESIDIO OSPEDALIERO SAN LUCA, VALLO DELLA LUCANIA; AZIENDA OSPEDALIERA UNIVERSITARIA “SAN GIOVANNI DI DIO E RUGGI D‘ARAGONA”, SALERNO; DE GASPERIS CARDIO CENTER GRANDE OSPEDALE METROPOLITANO NIGUARDA, MILANO; OSPEDALE SAN DONATO, AREZZO; AZIENDA SANITARIA UNIVERSITARIA “GIULIANO ISONTINA”, UNIVERSITÀ DI TRIESTE, TRIESTE; OSPEDALE UNIVERSITARIO DI ANVERSA, ANVERSA; AZIENDA OSPEDALIERA UNIVERSITAR
| | - E Ammirati
- PRESIDIO OSPEDALIERO SAN LUCA, VALLO DELLA LUCANIA; AZIENDA OSPEDALIERA UNIVERSITARIA “SAN GIOVANNI DI DIO E RUGGI D‘ARAGONA”, SALERNO; DE GASPERIS CARDIO CENTER GRANDE OSPEDALE METROPOLITANO NIGUARDA, MILANO; OSPEDALE SAN DONATO, AREZZO; AZIENDA SANITARIA UNIVERSITARIA “GIULIANO ISONTINA”, UNIVERSITÀ DI TRIESTE, TRIESTE; OSPEDALE UNIVERSITARIO DI ANVERSA, ANVERSA; AZIENDA OSPEDALIERA UNIVERSITAR
| | - A Tedeschi
- PRESIDIO OSPEDALIERO SAN LUCA, VALLO DELLA LUCANIA; AZIENDA OSPEDALIERA UNIVERSITARIA “SAN GIOVANNI DI DIO E RUGGI D‘ARAGONA”, SALERNO; DE GASPERIS CARDIO CENTER GRANDE OSPEDALE METROPOLITANO NIGUARDA, MILANO; OSPEDALE SAN DONATO, AREZZO; AZIENDA SANITARIA UNIVERSITARIA “GIULIANO ISONTINA”, UNIVERSITÀ DI TRIESTE, TRIESTE; OSPEDALE UNIVERSITARIO DI ANVERSA, ANVERSA; AZIENDA OSPEDALIERA UNIVERSITAR
| | - M Polito
- PRESIDIO OSPEDALIERO SAN LUCA, VALLO DELLA LUCANIA; AZIENDA OSPEDALIERA UNIVERSITARIA “SAN GIOVANNI DI DIO E RUGGI D‘ARAGONA”, SALERNO; DE GASPERIS CARDIO CENTER GRANDE OSPEDALE METROPOLITANO NIGUARDA, MILANO; OSPEDALE SAN DONATO, AREZZO; AZIENDA SANITARIA UNIVERSITARIA “GIULIANO ISONTINA”, UNIVERSITÀ DI TRIESTE, TRIESTE; OSPEDALE UNIVERSITARIO DI ANVERSA, ANVERSA; AZIENDA OSPEDALIERA UNIVERSITAR
| | - M Pieroni
- PRESIDIO OSPEDALIERO SAN LUCA, VALLO DELLA LUCANIA; AZIENDA OSPEDALIERA UNIVERSITARIA “SAN GIOVANNI DI DIO E RUGGI D‘ARAGONA”, SALERNO; DE GASPERIS CARDIO CENTER GRANDE OSPEDALE METROPOLITANO NIGUARDA, MILANO; OSPEDALE SAN DONATO, AREZZO; AZIENDA SANITARIA UNIVERSITARIA “GIULIANO ISONTINA”, UNIVERSITÀ DI TRIESTE, TRIESTE; OSPEDALE UNIVERSITARIO DI ANVERSA, ANVERSA; AZIENDA OSPEDALIERA UNIVERSITAR
| | - P Gentile
- PRESIDIO OSPEDALIERO SAN LUCA, VALLO DELLA LUCANIA; AZIENDA OSPEDALIERA UNIVERSITARIA “SAN GIOVANNI DI DIO E RUGGI D‘ARAGONA”, SALERNO; DE GASPERIS CARDIO CENTER GRANDE OSPEDALE METROPOLITANO NIGUARDA, MILANO; OSPEDALE SAN DONATO, AREZZO; AZIENDA SANITARIA UNIVERSITARIA “GIULIANO ISONTINA”, UNIVERSITÀ DI TRIESTE, TRIESTE; OSPEDALE UNIVERSITARIO DI ANVERSA, ANVERSA; AZIENDA OSPEDALIERA UNIVERSITAR
| | - M Merlo
- PRESIDIO OSPEDALIERO SAN LUCA, VALLO DELLA LUCANIA; AZIENDA OSPEDALIERA UNIVERSITARIA “SAN GIOVANNI DI DIO E RUGGI D‘ARAGONA”, SALERNO; DE GASPERIS CARDIO CENTER GRANDE OSPEDALE METROPOLITANO NIGUARDA, MILANO; OSPEDALE SAN DONATO, AREZZO; AZIENDA SANITARIA UNIVERSITARIA “GIULIANO ISONTINA”, UNIVERSITÀ DI TRIESTE, TRIESTE; OSPEDALE UNIVERSITARIO DI ANVERSA, ANVERSA; AZIENDA OSPEDALIERA UNIVERSITAR
| | - C Van De Heyning
- PRESIDIO OSPEDALIERO SAN LUCA, VALLO DELLA LUCANIA; AZIENDA OSPEDALIERA UNIVERSITARIA “SAN GIOVANNI DI DIO E RUGGI D‘ARAGONA”, SALERNO; DE GASPERIS CARDIO CENTER GRANDE OSPEDALE METROPOLITANO NIGUARDA, MILANO; OSPEDALE SAN DONATO, AREZZO; AZIENDA SANITARIA UNIVERSITARIA “GIULIANO ISONTINA”, UNIVERSITÀ DI TRIESTE, TRIESTE; OSPEDALE UNIVERSITARIO DI ANVERSA, ANVERSA; AZIENDA OSPEDALIERA UNIVERSITAR
| | - T Bekelaarh
- PRESIDIO OSPEDALIERO SAN LUCA, VALLO DELLA LUCANIA; AZIENDA OSPEDALIERA UNIVERSITARIA “SAN GIOVANNI DI DIO E RUGGI D‘ARAGONA”, SALERNO; DE GASPERIS CARDIO CENTER GRANDE OSPEDALE METROPOLITANO NIGUARDA, MILANO; OSPEDALE SAN DONATO, AREZZO; AZIENDA SANITARIA UNIVERSITARIA “GIULIANO ISONTINA”, UNIVERSITÀ DI TRIESTE, TRIESTE; OSPEDALE UNIVERSITARIO DI ANVERSA, ANVERSA; AZIENDA OSPEDALIERA UNIVERSITAR
| | - A Cipriani
- PRESIDIO OSPEDALIERO SAN LUCA, VALLO DELLA LUCANIA; AZIENDA OSPEDALIERA UNIVERSITARIA “SAN GIOVANNI DI DIO E RUGGI D‘ARAGONA”, SALERNO; DE GASPERIS CARDIO CENTER GRANDE OSPEDALE METROPOLITANO NIGUARDA, MILANO; OSPEDALE SAN DONATO, AREZZO; AZIENDA SANITARIA UNIVERSITARIA “GIULIANO ISONTINA”, UNIVERSITÀ DI TRIESTE, TRIESTE; OSPEDALE UNIVERSITARIO DI ANVERSA, ANVERSA; AZIENDA OSPEDALIERA UNIVERSITAR
| | - M Camilli
- PRESIDIO OSPEDALIERO SAN LUCA, VALLO DELLA LUCANIA; AZIENDA OSPEDALIERA UNIVERSITARIA “SAN GIOVANNI DI DIO E RUGGI D‘ARAGONA”, SALERNO; DE GASPERIS CARDIO CENTER GRANDE OSPEDALE METROPOLITANO NIGUARDA, MILANO; OSPEDALE SAN DONATO, AREZZO; AZIENDA SANITARIA UNIVERSITARIA “GIULIANO ISONTINA”, UNIVERSITÀ DI TRIESTE, TRIESTE; OSPEDALE UNIVERSITARIO DI ANVERSA, ANVERSA; AZIENDA OSPEDALIERA UNIVERSITAR
| | - T Sanna
- PRESIDIO OSPEDALIERO SAN LUCA, VALLO DELLA LUCANIA; AZIENDA OSPEDALIERA UNIVERSITARIA “SAN GIOVANNI DI DIO E RUGGI D‘ARAGONA”, SALERNO; DE GASPERIS CARDIO CENTER GRANDE OSPEDALE METROPOLITANO NIGUARDA, MILANO; OSPEDALE SAN DONATO, AREZZO; AZIENDA SANITARIA UNIVERSITARIA “GIULIANO ISONTINA”, UNIVERSITÀ DI TRIESTE, TRIESTE; OSPEDALE UNIVERSITARIO DI ANVERSA, ANVERSA; AZIENDA OSPEDALIERA UNIVERSITAR
| | - G Sinagra
- PRESIDIO OSPEDALIERO SAN LUCA, VALLO DELLA LUCANIA; AZIENDA OSPEDALIERA UNIVERSITARIA “SAN GIOVANNI DI DIO E RUGGI D‘ARAGONA”, SALERNO; DE GASPERIS CARDIO CENTER GRANDE OSPEDALE METROPOLITANO NIGUARDA, MILANO; OSPEDALE SAN DONATO, AREZZO; AZIENDA SANITARIA UNIVERSITARIA “GIULIANO ISONTINA”, UNIVERSITÀ DI TRIESTE, TRIESTE; OSPEDALE UNIVERSITARIO DI ANVERSA, ANVERSA; AZIENDA OSPEDALIERA UNIVERSITAR
| | - E Bonnefoy–cudraz
- PRESIDIO OSPEDALIERO SAN LUCA, VALLO DELLA LUCANIA; AZIENDA OSPEDALIERA UNIVERSITARIA “SAN GIOVANNI DI DIO E RUGGI D‘ARAGONA”, SALERNO; DE GASPERIS CARDIO CENTER GRANDE OSPEDALE METROPOLITANO NIGUARDA, MILANO; OSPEDALE SAN DONATO, AREZZO; AZIENDA SANITARIA UNIVERSITARIA “GIULIANO ISONTINA”, UNIVERSITÀ DI TRIESTE, TRIESTE; OSPEDALE UNIVERSITARIO DI ANVERSA, ANVERSA; AZIENDA OSPEDALIERA UNIVERSITAR
| | - T Bochaton
- PRESIDIO OSPEDALIERO SAN LUCA, VALLO DELLA LUCANIA; AZIENDA OSPEDALIERA UNIVERSITARIA “SAN GIOVANNI DI DIO E RUGGI D‘ARAGONA”, SALERNO; DE GASPERIS CARDIO CENTER GRANDE OSPEDALE METROPOLITANO NIGUARDA, MILANO; OSPEDALE SAN DONATO, AREZZO; AZIENDA SANITARIA UNIVERSITARIA “GIULIANO ISONTINA”, UNIVERSITÀ DI TRIESTE, TRIESTE; OSPEDALE UNIVERSITARIO DI ANVERSA, ANVERSA; AZIENDA OSPEDALIERA UNIVERSITAR
| | - A Hayek
- PRESIDIO OSPEDALIERO SAN LUCA, VALLO DELLA LUCANIA; AZIENDA OSPEDALIERA UNIVERSITARIA “SAN GIOVANNI DI DIO E RUGGI D‘ARAGONA”, SALERNO; DE GASPERIS CARDIO CENTER GRANDE OSPEDALE METROPOLITANO NIGUARDA, MILANO; OSPEDALE SAN DONATO, AREZZO; AZIENDA SANITARIA UNIVERSITARIA “GIULIANO ISONTINA”, UNIVERSITÀ DI TRIESTE, TRIESTE; OSPEDALE UNIVERSITARIO DI ANVERSA, ANVERSA; AZIENDA OSPEDALIERA UNIVERSITAR
| | - A Aloia
- PRESIDIO OSPEDALIERO SAN LUCA, VALLO DELLA LUCANIA; AZIENDA OSPEDALIERA UNIVERSITARIA “SAN GIOVANNI DI DIO E RUGGI D‘ARAGONA”, SALERNO; DE GASPERIS CARDIO CENTER GRANDE OSPEDALE METROPOLITANO NIGUARDA, MILANO; OSPEDALE SAN DONATO, AREZZO; AZIENDA SANITARIA UNIVERSITARIA “GIULIANO ISONTINA”, UNIVERSITÀ DI TRIESTE, TRIESTE; OSPEDALE UNIVERSITARIO DI ANVERSA, ANVERSA; AZIENDA OSPEDALIERA UNIVERSITAR
| |
Collapse
|
21
|
Serra W, Solinas E, Di Spigno F, Palumbo A, Tedeschi A, Vignali L, Barocelli F. Intercoronary communication and coronary artery fistula: when echocardiography could complete coronary-CTA and angiography. Acta Cardiol 2021; 76:665-667. [PMID: 32354301 DOI: 10.1080/00015385.2020.1757853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Walter Serra
- Cardiology Division, Cardio-Thoracic-Vascular Department, University Hospital of Parma, Parma, Italy
| | - Emilia Solinas
- Cardiology Division, Cardio-Thoracic-Vascular Department, University Hospital of Parma, Parma, Italy
| | - Francesco Di Spigno
- Cardiology Division, Cardio-Thoracic-Vascular Department, University Hospital of Parma, Parma, Italy
| | | | - Andrea Tedeschi
- Cardiology Division, Cardio-Thoracic-Vascular Department, University Hospital of Parma, Parma, Italy
| | - Luigi Vignali
- Cardiology Division, Cardio-Thoracic-Vascular Department, University Hospital of Parma, Parma, Italy
| | - Federico Barocelli
- Cardiology Division, Cardio-Thoracic-Vascular Department, University Hospital of Parma, Parma, Italy
| |
Collapse
|
22
|
Presley KF, Fan F, DiRando NM, Shahhosseini M, Rao JZ, Tedeschi A, Castro CE, Lannutti JJ. Injectable, dispersible polysulfone‐polysulfone core‐shell particles for optical oxygen sensing. J Appl Polym Sci 2021; 138. [DOI: 10.1002/app.50603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Kayla F. Presley
- Department of Materials Science and Engineering The Ohio State University Columbus Ohio USA
| | - Fan Fan
- Department of Materials Science and Engineering The Ohio State University Columbus Ohio USA
- Center for Chronic Brain Injury Program The Ohio State University Columbus Ohio USA
| | - Nicole M. DiRando
- Department of Materials Science and Engineering The Ohio State University Columbus Ohio USA
| | - Melika Shahhosseini
- Department of Mechanical and Aerospace Engineering The Ohio State University Columbus Ohio USA
| | - Jim Z. Rao
- Department of Materials Science and Engineering The Ohio State University Columbus Ohio USA
| | - Andrea Tedeschi
- Center for Chronic Brain Injury Program The Ohio State University Columbus Ohio USA
- Department of Neuroscience, Wexner Medical Center The Ohio State University Columbus Ohio USA
| | - Carlos E. Castro
- Department of Mechanical and Aerospace Engineering The Ohio State University Columbus Ohio USA
| | - John J. Lannutti
- Department of Materials Science and Engineering The Ohio State University Columbus Ohio USA
- Center for Chronic Brain Injury Program The Ohio State University Columbus Ohio USA
| |
Collapse
|
23
|
Tam CSL, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss B, Moreno C, Szafer‐Glusman E, Russell K, Zhou C, Ninomoto J, Dean JP, Ghia P, Wierda WG. CAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIXED‐DURATION IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL). Hematol Oncol 2021. [DOI: 10.1002/hon.32_2879] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- C. S. L Tam
- Peter MacCallum Cancer Center & St. Vincent's Hospital and the University of Melbourne Haematology and Disease Group, Melbourne VIC Australia
| | - J. N Allan
- Weill Cornell Medicine, Hematology/Oncology New York USA
| | - T Siddiqi
- City of Hope National Medical Center Hematology Duarte USA
| | - T. J Kipps
- UCSD Moores Cancer Center Chronic Lymphocytic Leukemia San Diego USA
| | - R Jacobs
- Levine Cancer Institute Hematology and Medical Oncology Charlotte USA
| | - S Opat
- Monash University, Clinical Haematology Clayton VIC Australia
| | - P. M Barr
- Wilmot Cancer Institute University of Rochester Medical Center Hematology/Oncology Rochester USA
| | - A Tedeschi
- ASST Grande Ospedale Metropolitano Niguarda Haematology Milan Italy
| | - L Trentin
- Hematology and Clinical Immunology Unit Department of Medicine University of Padova, Hematology Padova Italy
| | - R Bannerji
- Rutgers Cancer Institute of New Jersey Hematology/Oncology New Brunswick USA
| | - S Jackson
- Middlemore Hospital, Haematology Auckland New Zealand
| | - B Kuss
- Flinders University and Medical Centre Haemotology and Molecular Genetics, Bedford Park SA Australia
| | - C Moreno
- Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Hematology Barcelona Spain
| | - E Szafer‐Glusman
- Pharmacyclics LLC, an AbbVie Company, Translational Medicine Sunnyvale USA
| | - K Russell
- Pharmacyclics LLC, an AbbVie Company, Clinical Program Development Sunnyvale USA
| | - C Zhou
- Pharmacyclics LLC, an AbbVie Company, Biostatistics Sunnyvale USA
| | - J Ninomoto
- Pharmacyclics LLC, an AbbVie Company, Oncology Sunnyvale USA
| | - J. P Dean
- Pharmacyclics LLC, an AbbVie Company, Oncology Sunnyvale USA
| | - P Ghia
- ivision of Experimental Oncology Università Vita‐Salute San Raffaele and IRCCS Ospedale San Raffaele, Experimental Oncology Milan Italy
| | - W. G Wierda
- University of Texas MD Anderson Cancer Center Leukemia Houston USA
| |
Collapse
|
24
|
Trotman J, Tedeschi A, Linton K, McKay P, Hu B, Chan H, Jin J, Sobieraj‐Teague M, Zinzani PL, Coleman M, Browett P, Ke X, Sun M, Marcus R, Portell C, Thieblemont C, Zhou K, Liberati AM, Bachy E, Cavallo F, Costello R, Iyengar S, Marasca R, Mociková H, Kim JS, Talaulikar D, Co M, Zhou W, Huang J, Opat S. SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY). Hematol Oncol 2021. [DOI: 10.1002/hon.19_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- J. Trotman
- Concord Repatriation General Hospital University of Sydney Oncology Concord Australia
| | - A. Tedeschi
- ASST Grande Ospedale Metropolitano Niguarda Hematology Milan Italy
| | - K. Linton
- The Christie Hematology Manchester UK
| | - P. McKay
- Beatson West of Scotland Cancer Centre Oncology Glasgow UK
| | - B. Hu
- Levine Cancer Institute/Atrium Health Oncology Charlotte USA
| | - H. Chan
- North Shore Hospital Haematology Auckland New Zealand
| | - J. Jin
- The First Affiliated Hospital Zhejiang University Hematology Hangzhou China
| | | | - P. L. Zinzani
- Institute of Hematology “Seràgnoli” University of Bologna Hematology Bologna Italy
| | - M. Coleman
- Clinical Research Alliance Hematology Lake Success USA
| | - P. Browett
- Auckland City Hospital Haematology Grafton New Zealand
| | - X. Ke
- Peking University Third Hospital Hematology Beijing China
| | - M. Sun
- Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences Peking Union Medical College Hematology Tianjin China
| | - R. Marcus
- Sarah Cannon Research Institute UK Oncology London UK
| | - C. Portell
- University of Virginia Health System Hematology/Oncology Charlottesville USA
| | - C. Thieblemont
- APHP, Hôpital Saint‐Louis, Hemato‐oncology Paris University Diderot Hematology/Oncology Paris France
| | - K. Zhou
- Henan Cancer Hospital Oncology Zhengzhou China
| | - A. M. Liberati
- Azienda Ospedaliera Santa Maria Di Terni Oncology Terni Italy
| | - E. Bachy
- Centre Hospitalier Lyon Sud Pierre Bénite Hematology Rhone Italy
| | - F. Cavallo
- Azienda Ospedaliera Città della Salute e della Scienza di Torino Hematology Torino Italy
| | - Rég. Costello
- Hôpital de la Conception – APHM Hematology Marseille France
| | - S. Iyengar
- Royal Marsden Hospital Haematology London UK
| | - R. Marasca
- AOU Policlinico di Modena Hematology Modena Italy
| | - H. Mociková
- Fakultní nemocnice Královské Vinohrady Hematology Praha 10 Czech Republic
| | - J. S. Kim
- Severance Hospital Hematology Seoul Korea
| | - D. Talaulikar
- The Canberra Hospital Haematology Canberra Australia
| | - M. Co
- BeiGene (Beijing) Co., Ltd. Beijing, China and BeiGene USA, Inc Hematology San Mateo USA
| | - W. Zhou
- BeiGene (Beijing) Co., Ltd. Beijing, China and BeiGene USA, Inc Hematology San Mateo USA
| | - J. Huang
- BeiGene (Beijing) Co., Ltd. Beijing, China and BeiGene USA, Inc Hematology San Mateo USA
| | - S. Opat
- Monash Health Monash University Haematology Clayton Australia
| |
Collapse
|
25
|
Condoluci A, Terzi‐di‐Bergamo L, Forestieri G, Moia R, Deambrogi C, Deodato M, Frustaci AM, Merli M, Mattarucchi R, Autore F, Fahrni G, Scarfò L, Gussetti D, Bulian P, Zanatta A, Spina V, Faderl MR, Bruscaggin A, Pini K, Piffaretti D, Koch R, Pirosa MC, Cittone MG, Passweg J, Cavalli F, Zucca E, Gerber B, Gillessen S, Stüssi G, Gattei V, Ghia P, Gregor M, Laurenti L, Passamonti F, Tedeschi A, Gaidano G, Rossi D. IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA. Hematol Oncol 2021. [DOI: 10.1002/hon.45_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Condoluci
- Oncology Institute of Southern Switzerland Clinic of Hematology Bellinzona Switzerland
| | - L. Terzi‐di‐Bergamo
- Institute of Oncology Research Laboratory of Experimental Hematology Bellinzona Switzerland
| | - G. Forestieri
- Institute of Oncology Research Laboratory of Experimental Hematology Bellinzona Switzerland
| | - R. Moia
- University of Eastern Piedmont Department of Translational Medicine, , Division of Hematology Novara Italy
| | - C. Deambrogi
- University of Eastern Piedmont Department of Translational Medicine, , Division of Hematology Novara Italy
| | - M. Deodato
- ASST Grande Ospedale Metropolitano Niguarda Niguarda Cancer Center, Department of Hematology Milan Italy
| | - A. M. Frustaci
- ASST Grande Ospedale Metropolitano Niguarda Niguarda Cancer Center, Department of Hematology Milan Italy
| | - M. Merli
- University of Insubria Ospedale di Circolo e Fondazione Macchi, Department of Hematology Varese Italy
| | - R. Mattarucchi
- University of Insubria Ospedale di Circolo e Fondazione Macchi, Department of Hematology Varese Italy
| | - F. Autore
- Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Hearth, Hematology Institute Rome Italy
| | - G. Fahrni
- Cantonal Hospital Lucerne Division of Haematology and Central Haematology Laboratory Lucerne Switzerland
| | - L. Scarfò
- IRCCS San Raffaele Scientific Institute and Vita‐Salute San Raffaele University Strategic Research Program on CLL, Division of Experimental Oncology Milan Italy
| | - D. Gussetti
- Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Clinical and Experimental Onco‐Hematology Unit Aviano Italy
| | - P. Bulian
- Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Clinical and Experimental Onco‐Hematology Unit Aviano Italy
| | - A. Zanatta
- Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Clinical and Experimental Onco‐Hematology Unit Aviano Italy
| | - V. Spina
- Institute of Oncology Research Laboratory of Experimental Hematology Bellinzona Switzerland
| | - M. R. Faderl
- Oncology Institute of Southern Switzerland Clinic of Hematology Bellinzona Switzerland
| | - A. Bruscaggin
- Institute of Oncology Research Laboratory of Experimental Hematology Bellinzona Switzerland
| | - K. Pini
- Institute of Oncology Research Laboratory of Experimental Hematology Bellinzona Switzerland
| | - D. Piffaretti
- Institute of Oncology Research Laboratory of Experimental Hematology Bellinzona Switzerland
| | - R. Koch
- Institute of Oncology Research Laboratory of Experimental Hematology Bellinzona Switzerland
| | - M. C. Pirosa
- Oncology Institute of Southern Switzerland Clinic of Hematology Bellinzona Switzerland
| | - M. G. Cittone
- Oncology Institute of Southern Switzerland Clinic of Hematology Bellinzona Switzerland
| | - J. Passweg
- University Hospital Basel Department of Haematology Basel Switzerland
| | - F. Cavalli
- Università della Svizzera Italiana Institute of Oncology Research Bellinzona Switzerland
| | - E. Zucca
- Oncology Institute of Southern Switzerland Clinic of Oncology Bellinzona Switzerland
| | - B. Gerber
- Oncology Institute of Southern Switzerland Clinic of Hematology Bellinzona Switzerland
| | - S. Gillessen
- Oncology Institute of Southern Switzerland Clinic of Oncology Bellinzona Switzerland
| | - G. Stüssi
- Oncology Institute of Southern Switzerland Clinic of Hematology Bellinzona Switzerland
| | - V. Gattei
- Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Clinical and Experimental Onco‐Hematology Unit Aviano Italy
| | - P. Ghia
- IRCCS San Raffaele Scientific Institute and Vita‐Salute San Raffaele University Strategic Research Program on CLL, Division of Experimental Oncology Milan Italy
| | - M. Gregor
- Cantonal Hospital Lucerne Division of Haematology and Central Haematology Laboratory Lucerne Switzerland
| | - L. Laurenti
- Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Hearth, Hematology Institute Rome Italy
| | - F. Passamonti
- University of Insubria Ospedale di Circolo e Fondazione Macchi, Department of Hematology Varese Italy
| | - A. Tedeschi
- ASST Grande Ospedale Metropolitano Niguarda Niguarda Cancer Center, Department of Hematology Milan Italy
| | - G. Gaidano
- University of Eastern Piedmont Department of Translational Medicine, , Division of Hematology Novara Italy
| | - D. Rossi
- Oncology Institute of Southern Switzerland Clinic of Hematology Bellinzona Switzerland
| |
Collapse
|
26
|
Coutre SE, Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Dai S, Szoke A, Dean JP, Kipps TJ, Ghia P. FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 7‐YEAR RESULTS FROM RESONATE‐2. Hematol Oncol 2021. [DOI: 10.1002/hon.48_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- S. E. Coutre
- Stanford Cancer Center, Stanford University School of Medicine, Stanford California USA
| | - P. M. Barr
- Wilmot Cancer Institute, University of Rochester Medical Center, Clinical Trials Office Rochester USA
| | - C. Owen
- Tom Baker Cancer Centre, University of Calgary, Medicine and Oncology Calgary Canada
| | - T. Robak
- Medical University of Lodz, Copernicus Memorial Hospital, Hematology Lodz Poland
| | - A. Tedeschi
- ASST Grande Ospedale Metropolitano Niguarda, Hematology Milan Italy
| | - O. Bairey
- Rabin Medical Center, Life and Medicine Sciences Petah Tikva Israel
| | - J. A. Burger
- University of Texas MD Anderson Cancer Center, Leukemia Houston USA
| | - P. Hillmen
- The Leeds Teaching Hospitals, St. James Institute of Oncology, Oncology Leeds UK
| | - S. Devereux
- Kings College Hospital, NHS Foundation Trust, Lymphoma Biology London UK
| | - S. Grosicki
- School of Public Health, Silesian Medical University, Hematology and Cancer Prevention Katowice Poland
| | - H. McCarthy
- Royal Bournemouth General Hospital, Hematology Bournemouth UK
| | - J. Li
- Jiangsu Province Hospital, Hematology Nanjing China
| | - D. Simpson
- North Shore Hospital, Hematology Auckland New Zealand
| | - F. Offner
- Universitair Ziekenhuis Gent, Internal Medicine and Pediatrics Gent Belgium
| | - C. Moreno
- Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Hematology Barcelona Spain
| | - S. Dai
- Pharmacyclics LLC, an AbbVie Company, Biostatistics Sunnyvale USA
| | - A. Szoke
- Pharmacyclics LLC, an AbbVie Company, Oncology Sunnyvale USA
| | - J. P. Dean
- Pharmacyclics LLC, an AbbVie Company, Oncology Sunnyvale USA
| | - T. J. Kipps
- UCSD Moores Cancer Center, Blood Cancer Research Fund San Diego USA
| | - P. Ghia
- Università Vita‐Salute San Raffaele and IRCCS Ospedale San Raffaele, Medical Oncology Milan Italy
| |
Collapse
|
27
|
Terzi di Bergamo L, Forestieri G, Loh JW, Singh A, Spina V, Zucchetto A, Condoluci A, Faderl M, Koch R, Bruscaggin A, Pini K, Wu W, Piffaretti D, Bittolo T, Tissino E, Paoli L, Deambrogi C, Frustaci AM, Autore F, Merli M, Scarfò L, Rasi S, Passweg J, Moia R, Martines C, Ghia P, Cavalli F, Zucca E, Gerber B, Gillessen S, Stüssi G, Montillo M, Passamonti F, Gregor M, Laurenti L, Tedeschi A, Gaidano G, Efremov D, Gattei V, Khiabanian H, Rossi D. ADAPTATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO IBRUTINIB IS MEDIATED BY EPIGENETIC PLASTICITY OF RESIDUAL DISEASE AND BY‐PASS SIGNALING VIA MAPK PATHWAY. Hematol Oncol 2021. [DOI: 10.1002/hon.29_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
28
|
Frustaci AM, Tedeschi A, Zinzani PL, Pietrasanta D, Coscia M, Zenz T, Motta M, Gaidano G, Scarfò L, Deodato M, Zamprogna G, Vitale C, Cairoli R, Rossi D, Montillo M. MOLTO, A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II CLINICAL TRIAL ON VENETOCLAX, ATEZOLIZUMAB, OBINUTUZUMAB IN RICHTER TRANSFORMATION: SAFETY INTERIM ANALYSIS. Hematol Oncol 2021. [DOI: 10.1002/hon.40_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. M. Frustaci
- ASST Grande Ospedale Metropolitano Niguarda Hematology Milan Italy
| | - A. Tedeschi
- ASST Grande Ospedale Metropolitano Niguarda Hematology Milan Italy
| | - P. L. Zinzani
- "L. e A. Seràgnoli," University of Bologna Hematology Bologna Italy
| | - D. Pietrasanta
- Azienda Ospedaliera SS Arrigo e Biagio e Cesare Arrigo Hematology Alessandria Italy
| | - M. Coscia
- A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences University of Torino Hematology Torino Italy
| | - T. Zenz
- University Hospital Zürich and University of Zürich Hematology Zurich Switzerland
| | - M. Motta
- ASST Spedali Civili Hematology Brescia Italy
| | - G. Gaidano
- University of Eastern Piedmont Translational Medicine, Division of Hematology Novara Italy
| | - L. Scarfò
- Università Vita‐Salute San Raffaele and IRCC Ospedale San Raffaele Hematology Milano Italy
| | - M. Deodato
- ASST Grande Ospedale Metropolitano Niguarda Hematology Milan Italy
| | - G. Zamprogna
- ASST Grande Ospedale Metropolitano Niguarda Hematology Milan Italy
| | - C. Vitale
- A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences University of Torino Hematology Torino Italy
| | - R. Cairoli
- ASST Grande Ospedale Metropolitano Niguarda Hematology Milan Italy
| | - D. Rossi
- Oncology Institute of Southern Switzerland; Institute of Oncology Research Hematology Bellinzona Switzerland
| | - M. Montillo
- ASST Grande Ospedale Metropolitano Niguarda Hematology Milan Italy
| |
Collapse
|
29
|
Tedeschi A, Agostoni P, Pezzuto B, Corra’ U, Scrutinio D, La Gioia R, Raimondo R, Passantino A, Piepoli MF. Role of comorbidities in heart failure prognosis Part 2: Chronic kidney disease, elevated serum uric acid. Eur J Prev Cardiol 2020; 27:35-45. [PMID: 33238740 PMCID: PMC7691631 DOI: 10.1177/2047487320957793] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Accepted: 08/18/2020] [Indexed: 12/18/2022]
Abstract
Despite improvements in pharmacotherapy, morbidity and mortality rates in community-based populations with chronic heart failure still remain high. The increase in medical complexity among patients with heart failure may be reflected by an increase in concomitant non-cardiovascular comorbidities, which are recognized as independent prognostic factors in this population. Heart failure and chronic kidney disease share many risk factors, and often coexist. The presence of kidney failure is associated with incremented risk of cardiovascular and non-cardiovascular mortality in heart failure patients. Chronic kidney disease is also linked with underutilization of evidence-based heart failure therapy that may reduce morbidity and mortality. More targeted therapies would be important to improve the prognosis of patients with these diseases. In recent years, serum uric acid as a determinant of cardiovascular risk has gained interest. Epidemiological, experimental and clinical data show that patients with hyperuricaemia are at increased risk of cardiac, renal and vascular damage and cardiovascular events. Moreover, elevated serum uric acid predicts worse outcome in both acute and chronic heart failure. While studies have raised the possibility of preventing heart failure through the use of uric acid lowering agents, the literature is still inconclusive on whether the reduction in uric acid will result in a measurable clinical benefit. Available evidences suggest that chronic kidney disease and elevated uric acid could worsen heart failure patients' prognosis. The aim of this review is to analyse a possible utilization of these comorbidities in risk stratification and as a therapeutic target to get a prognostic improvement in heart failure patients.
Collapse
Affiliation(s)
- Andrea Tedeschi
- Cardiology Dept, Guglielmo da Saliceto Hospital, AUSL Piacenza
and University of Parma, Italy
| | - Piergiuseppe Agostoni
- Clinical Cardiology and Rehabilitation Unit, Università degli
Studi di Milano, Centro Cardiologico Monzino IRCCS, Italy
| | - Beatrice Pezzuto
- Clinical Cardiology and Rehabilitation Unit, Università degli
Studi di Milano, Centro Cardiologico Monzino IRCCS, Italy
| | - Ugo Corra’
- Centro Cardiologico di Veruno, Istituti Clinici Maugeri,
Italy
| | - Domenico Scrutinio
- Istituti Clinici Scientifici Maugeri-SPA SB. I.R.C.C.S.
Institute of Bari, Italy
| | - Rocco La Gioia
- Istituti Clinici Scientifici Maugeri-SPA SB. I.R.C.C.S.
Institute of Bari, Italy
| | - Rosa Raimondo
- Istituti Clinici Scientifici Maugeri-SPA SB. I.R.C.C.S.
Institute of Bari, Italy
| | - Andrea Passantino
- Istituti Clinici Scientifici Maugeri-SPA SB. I.R.C.C.S.
Institute of Bari, Italy
| | - Massimo F Piepoli
- Cardiology Dept, Guglielmo da Saliceto Hospital, AUSL Piacenza
and University of Parma, Italy
| |
Collapse
|
30
|
Sun W, Larson MJ, Kiyoshi CM, Annett AJ, Stalker WA, Peng J, Tedeschi A. Gabapentinoid treatment promotes corticospinal plasticity and regeneration following murine spinal cord injury. J Clin Invest 2020; 130:345-358. [PMID: 31793909 DOI: 10.1172/jci130391] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Accepted: 10/02/2019] [Indexed: 02/06/2023] Open
Abstract
Axon regeneration failure causes neurological deficits and long-term disability after spinal cord injury (SCI). Here, we found that the α2δ2 subunit of voltage-gated calcium channels negatively regulates axon growth and regeneration of corticospinal neurons, the cells that originate the corticospinal tract. Increased α2δ2 expression in corticospinal neurons contributed to loss of corticospinal regrowth ability during postnatal development and after SCI. In contrast, α2δ2 pharmacological blockade through gabapentin administration promoted corticospinal structural plasticity and regeneration in adulthood. Using an optogenetic strategy combined with in vivo electrophysiological recording, we demonstrated that regenerating corticospinal axons functionally integrate into spinal circuits. Mice administered gabapentin recovered upper extremity function after cervical SCI. Importantly, such recovery relies on reorganization of the corticospinal pathway, as chemogenetic silencing of injured corticospinal neurons transiently abrogated recovery. Thus, targeting α2δ2 with a clinically relevant treatment strategy aids repair of motor circuits after SCI.
Collapse
Affiliation(s)
- Wenjing Sun
- Department of Neuroscience, Wexner Medical Center
| | | | | | | | | | - Juan Peng
- Center for Biostatistics and Bioinformatics, and
| | - Andrea Tedeschi
- Department of Neuroscience, Wexner Medical Center.,Chronic Brain Injury Program, The Ohio State University, Columbus, Ohio, USA
| |
Collapse
|
31
|
Kiyoshi C, Tedeschi A. Axon growth and synaptic function: A balancing act for axonal regeneration and neuronal circuit formation in CNS trauma and disease. Dev Neurobiol 2020; 80:277-301. [PMID: 32902152 PMCID: PMC7754183 DOI: 10.1002/dneu.22780] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Revised: 08/29/2020] [Accepted: 08/31/2020] [Indexed: 12/13/2022]
Abstract
Axons in the adult mammalian central nervous system (CNS) fail to regenerate inside out due to intrinsic and extrinsic neuronal determinants. During CNS development, axon growth, synapse formation, and function are tightly regulated processes allowing immature neurons to effectively grow an axon, navigate toward target areas, form synaptic contacts and become part of information processing networks that control behavior in adulthood. Not only immature neurons are able to precisely control the expression of a plethora of genes necessary for axon extension and pathfinding, synapse formation and function, but also non-neuronal cells such as astrocytes and microglia actively participate in sculpting the nervous system through refinement, consolidation, and elimination of synaptic contacts. Recent evidence indicates that a balancing act between axon regeneration and synaptic function may be crucial for rebuilding functional neuronal circuits after CNS trauma and disease in adulthood. Here, we review the role of classical and new intrinsic and extrinsic neuronal determinants in the context of CNS development, injury, and disease. Moreover, we discuss strategies targeting neuronal and non-neuronal cell behaviors, either alone or in combination, to promote axon regeneration and neuronal circuit formation in adulthood.
Collapse
Affiliation(s)
- Conrad Kiyoshi
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA
| | - Andrea Tedeschi
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA
- Discovery Theme on Chronic Brain Injury, The Ohio State University, Columbus, OH 43210, USA
| |
Collapse
|
32
|
Abstract
Microvascular complications are often associated with slow and progressive damage of various organs. Pericytes are multi-functional mural cells of the microcirculation that control blood flow, vascular permeability and homeostasis. Whereas accumulating evidence suggests that these cells are also implicated in a variety of diseases, pericytes represent promising targets that can be manipulated for therapeutic gain. Here, we review the role of pericytes in angiogenesis, blood-brain barrier (BBB) function, neuroinflammation, tissue fibrosis, axon regeneration failure, and neurodegeneration. In addition, we outline strategies altering pericyte behavior to point out problems and promises for axon regeneration and central nervous system (CNS) repair following injury or disease.
Collapse
Affiliation(s)
- Fabio Laredo
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH, United States.,Department of Life Sciences, University of Nottingham, Nottingham, United Kingdom
| | - Julia Plebanski
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH, United States
| | - Andrea Tedeschi
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, OH, United States.,Discovery Theme on Chronic Brain Injury, The Ohio State University, Columbus, OH, United States
| |
Collapse
|
33
|
Tedeschi A, Dupraz S, Curcio M, Laskowski CJ, Schaffran B, Flynn KC, Santos TE, Stern S, Hilton BJ, Larson MJE, Gurniak CB, Witke W, Bradke F. ADF/Cofilin-Mediated Actin Turnover Promotes Axon Regeneration in the Adult CNS. Neuron 2019; 103:1073-1085.e6. [PMID: 31400829 DOI: 10.1016/j.neuron.2019.07.007] [Citation(s) in RCA: 58] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2019] [Revised: 06/06/2019] [Accepted: 07/08/2019] [Indexed: 11/27/2022]
Abstract
Injured axons fail to regenerate in the adult CNS, which contrasts with their vigorous growth during embryonic development. We explored the potential of re-initiating axon extension after injury by reactivating the molecular mechanisms that drive morphogenetic transformation of neurons during development. Genetic loss- and gain-of-function experiments followed by time-lapse microscopy, in vivo imaging, and whole-mount analysis show that axon regeneration is fueled by elevated actin turnover. Actin depolymerizing factor (ADF)/cofilin controls actin turnover to sustain axon regeneration after spinal cord injury through its actin-severing activity. This pinpoints ADF/cofilin as a key regulator of axon growth competence, irrespective of developmental stage. These findings reveal the central role of actin dynamics regulation in this process and elucidate a core mechanism underlying axon growth after CNS trauma. Thereby, neurons maintain the capacity to stimulate developmental programs during adult life, expanding their potential for plasticity. Thus, actin turnover is a key process for future regenerative interventions.
Collapse
Affiliation(s)
- Andrea Tedeschi
- Axonal Growth and Regeneration, German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Str. 27, 53127 Bonn, Germany
| | - Sebastian Dupraz
- Axonal Growth and Regeneration, German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Str. 27, 53127 Bonn, Germany
| | - Michele Curcio
- Axonal Growth and Regeneration, German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Str. 27, 53127 Bonn, Germany
| | - Claudia J Laskowski
- Axonal Growth and Regeneration, German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Str. 27, 53127 Bonn, Germany
| | - Barbara Schaffran
- Axonal Growth and Regeneration, German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Str. 27, 53127 Bonn, Germany
| | - Kevin C Flynn
- Axonal Growth and Regeneration, German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Str. 27, 53127 Bonn, Germany
| | - Telma E Santos
- Axonal Growth and Regeneration, German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Str. 27, 53127 Bonn, Germany
| | - Sina Stern
- Axonal Growth and Regeneration, German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Str. 27, 53127 Bonn, Germany
| | - Brett J Hilton
- Axonal Growth and Regeneration, German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Str. 27, 53127 Bonn, Germany
| | - Molly J E Larson
- Center for Brain and Spinal Cord Repair, Department of Neuroscience, Wexner Medical Center, The Ohio State University, 460 W. 12th Ave., Columbus, OH 43210, USA
| | - Christine B Gurniak
- Institute of Genetics, University of Bonn, Karlrobert-Kreiten-Str. 13, 53115 Bonn, Germany
| | - Walter Witke
- Institute of Genetics, University of Bonn, Karlrobert-Kreiten-Str. 13, 53115 Bonn, Germany
| | - Frank Bradke
- Axonal Growth and Regeneration, German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Str. 27, 53127 Bonn, Germany.
| |
Collapse
|
34
|
Montillo M, Rossi D, Zucca E, Frustaci A, Pileri S, Cavalli F, Tedeschi A. A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II TRIAL EVALUATING SAFETY AND EFFICACY OF VENETOCLAX, ATEZOLIZUMAB ANDOBINUTUZUMAB IN RICHTER TRANSFORMATION FROM CLL. Hematol Oncol 2019. [DOI: 10.1002/hon.4_2632] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Montillo
- Department of Haematology; Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda; Milano Italy
| | - D. Rossi
- Oncology; Università della Svizzera italiana, Institute of Oncology Research; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - E. Zucca
- Oncology; Università della Svizzera italiana, Institute of Oncology Research; Oncology Institute of Southern Switzerland; International Extranodal Lymphoma Study Group, IELSG; Bellinzona Switzerland
| | - A.M. Frustaci
- Department of Haematology; Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda; Milano Italy
| | - S. Pileri
- Haematopathology Division; European Institute of Oncology; Milano Italy
| | - F. Cavalli
- Oncology; Università della Svizzera italiana, Institute of Oncology Research; Oncology Institute of Southern Switzerland; International Extranodal Lymphoma Study Group, IELSG; Bellinzona Switzerland
| | - A. Tedeschi
- Department of Haematology; Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda; Milano Italy
| |
Collapse
|
35
|
Castillo J, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre T, Chavez J, Shain K, Issa S, Palomba L, Pasvolsky O, Simpson D, Talaulikar D, Tam C, Tedeschi A, Ansell S, Nayak L, Treon S. IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME: A RETROSPECTIVE, MULTICENTER STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.140_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J. Castillo
- Bing Center for Waldenstrom Macroglobulinemia; Dana-Farber Cancer Institute; Boston United States
| | - G. Itchaki
- Hematology; Rabin Medical Center; Petah Tikva Israel
| | - J. Paludo
- Hematology and Oncology; Mayo Clinic; Rochester United States
| | - M. Varettoni
- Hematology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - C. Buske
- Comprehensive Cancer Center; University Hospital Ulm; Ulm Germany
| | - T. Eyre
- Hematology; Churchill Hospital; Oxford United Kingdom
| | - J. Chavez
- Malignant Hematology; Moffitt Cancer Institute; Tampa United States
| | - K. Shain
- Malignant Hematology; Moffitt Cancer Institute; Tampa United States
| | - S. Issa
- Hematology; Middlemore Hospital; Auckland New Zealand
| | - L. Palomba
- Hematology and Oncology; Memorial Sloan Kettering Cancer Center; New York United States
| | - O. Pasvolsky
- Hematology; Rabin Medical Center; Petah Tikva Israel
| | - D. Simpson
- Hematology; North Shore Hospital; Auckland New Zealand
| | | | - C. Tam
- Hematology; Peter MacCallum Cancer Centre; Melbourne Australia
| | | | - S. Ansell
- Hematology and Oncology; Mayo Clinic; Rochester United States
| | - L. Nayak
- Center for CNS Lymphoma; Dana-Farber Cancer Institute; Boston United States
| | - S. Treon
- Bing Center for Waldenstrom Macroglobulinemia; Dana-Farber Cancer Institute; Boston United States
| |
Collapse
|
36
|
Tedeschi A, Burger J, Barr P, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean J, Kipps T. FIVE-YEAR FOLLOW-UP OF FIRST-LINE IBRUTINIB FOR TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA//SMALL LYMPHOCYTIC LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.67_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Tedeschi
- Department of Hematology; ASST Grande Ospedale Metropolitano Niguarda; Milan Italy
| | - J. Burger
- Department of Leukemia; University of Texas MD Anderson Cancer Center; Houston TX United States
| | - P.M. Barr
- Department of Medicine, Wilmot Cancer Institute; University of Rochester Medical Center; Rochester NY United States
| | - T. Robak
- Department of Hematology, Medical University of Lodz; Copernicus Memorial Hospital; Lodz Poland
| | - C. Owen
- Department of Oncology; Tom Baker Cancer Centre, University of Calgary; Calgary AB Canada
| | - P. Ghia
- Department of Experimental Oncology; Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele; Milan Italy
| | - O. Bairey
- Department of Hematology; Rabin Medical Center; Petah Tikva Israel
| | - P. Hillmen
- Department of Medicine, The Leeds Teaching Hospitals; St. James Institute of Oncology; Leeds United Kingdom
| | - S. Coutre
- Department of Medicine, Stanford Cancer Center; Stanford University School of Medicine; Stanford CA United States
| | - S. Devereux
- Department of Hematology; Kings College Hospital, NHS Foundation Trust; London United Kingdom
| | - S. Grosicki
- Department of Internal Medicine; School of Public Health, Silesian Medical University; Katowice Poland
| | - H. McCarthy
- Department of Hematology; Royal Bournemouth General Hospital; Bournemouth United Kingdom
| | - J. Li
- Department of Medicine; Jiangsu Province Hospital; Nanjing China
| | - D. Simpson
- Department of Hematology; North Shore Hospital; Auckland New Zealand
| | - F. Offner
- Department of Clinical Hematology; Universitair Ziekenhuis Gent; Gent Belgium
| | - C. Moreno
- Department of Hematology; Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona; Barcelona Spain
| | - S. Dai
- Department of Biostatistics; Pharmacyclics LLC, an AbbVie Company; Sunnyvale CA United States
| | - I. Lal
- Department of Clinical Science; Pharmacyclics LLC, an AbbVie Company; Sunnyvale CA United States
| | - J.P. Dean
- Department of Clinical Science; Pharmacyclics LLC, an AbbVie Company; Sunnyvale CA United States
| | - T.J. Kipps
- Department of Medicine; UCSD Moores Cancer Center; La Jolla CA United States
| |
Collapse
|
37
|
Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C. Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30:860-862. [PMID: 30520968 DOI: 10.1093/annonc/mdy466] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Hilton BJ, Blanquie O, Tedeschi A, Bradke F. High-resolution 3D imaging and analysis of axon regeneration in unsectioned spinal cord with or without tissue clearing. Nat Protoc 2019; 14:1235-1260. [DOI: 10.1038/s41596-019-0140-z] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Accepted: 01/17/2019] [Indexed: 12/12/2022]
|
39
|
Abstract
Traumatic brain and spinal cord injuries cause permanent disability. Although progress has been made in understanding the cellular and molecular mechanisms underlying the pathophysiological changes that affect both structure and function after injury to the brain or spinal cord, there are currently no cures for either condition. This may change with the development and application of multi-layer omics, new sophisticated bioinformatics tools, and cutting-edge imaging techniques. Already, these technical advances, when combined, are revealing an unprecedented number of novel cellular and molecular targets that could be manipulated alone or in combination to repair the injured central nervous system with precision. In this review, we highlight recent advances in applying these new technologies to the study of axon regeneration and rebuilding of injured neural circuitry. We then discuss the challenges ahead to translate results produced by these technologies into clinical application to help improve the lives of individuals who have a brain or spinal cord injury.
Collapse
Affiliation(s)
- Andrea Tedeschi
- Department of Neuroscience and Discovery Themes Initiative, College of Medicine, Ohio State University, Columbus, Ohio, 43210, USA
| | - Phillip G Popovich
- Center for Brain and Spinal Cord Repair, Institute for Behavioral Medicine Research, Ohio State University, Columbus, Ohio, 43210, USA
| |
Collapse
|
40
|
Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C. Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29:iv270. [PMID: 30285219 DOI: 10.1093/annonc/mdy322] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C. Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29:iv41-iv50. [PMID: 29982402 DOI: 10.1093/annonc/mdy146] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/08/2023] Open
Affiliation(s)
- E Kastritis
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - V Leblond
- Department of Hematology, Pitié Salpêtrière Hospital, Pierre and Marie Curie University, UPMC GRC11-GRECHY, Paris, France
| | - M A Dimopoulos
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - E Kimby
- Division of Hematology, Department of Medicine at Huddinge, Karolinska Institute and University Hospital, Stockholm, Sweden
| | - P Staber
- Division of Hematology and Hemostaseology, Department of Internal Medicine I, Vienna General Hospital, Vienna, Austria
| | - M J Kersten
- Department of Hematology, Academic Medical Center
- LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, The Netherlands
| | - A Tedeschi
- Department of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | - C Buske
- Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany
| |
Collapse
|
42
|
Abstract
Aims The study was carried out to investigate the efficacy and toxicity of fludarabine phosphate in the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in previously treated patients. Methods Sixteen patients, 11 males and 5 females, 9 in stage B and 7 in stage C, according to the Binet Staging System, were treated with a maximum of 6 cycles of fludarabine (25 mg/m2) for 5 days, every 4 weeks. All patients had been pretreated, 10 were refractory to standard regimens, 5 were in relapse, and 1 patient was in partial remission. Results Thirteen patients were judged suitable for evaluation. Overall 9 patients were responsive to treatment; 4 complete and 5 partial responses were observed. Of the 4 patients in complete remission, 3 were alive at 6, 10 and 13 months, respectively, from the beginning of treatment. One patient died after 11 months for acute graft-versus-host disease after allogenic bone marrow transplantation by an HLA sibling donor. Two of the 5 patients in partial remission were alive at 7 and 17 months, respectively, and the other 3 died (2 of disease reexpansion after 14 and 16 months and 1 of septic shock following pneumonia). Four patients were not responsive to treatment: 1 died from disease progression after 8 months from the beginning of therapy, 1 from cardiac failure after 9 months, 1 from septic shock following meningitis, and 1 was alive after 7 months of follow-up. Treatment was well tolerated, with nausea and vomiting in only one patient. We observed two episodes of pneumonitis, without any evidence of the responsible agent, a tumor lysis syndrome with acute renal failure, a recurrence of autoimmune thrombocytopenia, and a Coombs-positive hemolytic anemia. Conclusions Fludarabine phosphate is effective in the treatment of patients with advanced B-CLL, even in those refractory to multiple chemotherapy regimens.
Collapse
Affiliation(s)
- M Montillo
- Clinica di Ematologia, Torrette University Hospital, Ancona, Italy
| | | | | | | | | | | |
Collapse
|
43
|
Micali G, Dall'Oglio F, Tedeschi A, Lacarrubba F. Erythema‐directed digital photography for the enhanced evaluation of topical treatments for acne vulgaris. Skin Res Technol 2018; 24:440-444. [DOI: 10.1111/srt.12448] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/04/2018] [Indexed: 11/28/2022]
Affiliation(s)
- G. Micali
- Dermatology ClinicUniversity of Catania Catania Italy
| | - F. Dall'Oglio
- Dermatology ClinicUniversity of Catania Catania Italy
| | - A. Tedeschi
- Dermatology ClinicUniversity of Catania Catania Italy
| | - F. Lacarrubba
- Dermatology ClinicUniversity of Catania Catania Italy
| |
Collapse
|
44
|
Prüss H, Tedeschi A, Thiriot A, Lynch L, Loughhead SM, Stutte S, Mazo IB, Kopp MA, Brommer B, Blex C, Geurtz LC, Liebscher T, Niedeggen A, Dirnagl U, Bradke F, Volz MS, DeVivo MJ, Chen Y, von Andrian UH, Schwab JM. Spinal cord injury-induced immunodeficiency is mediated by a sympathetic-neuroendocrine adrenal reflex. Nat Neurosci 2017; 20:1549-1559. [PMID: 28920935 DOI: 10.1038/nn.4643] [Citation(s) in RCA: 106] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2017] [Accepted: 08/24/2017] [Indexed: 01/31/2023]
Abstract
Acute spinal cord injury (SCI) causes systemic immunosuppression and life-threatening infections, thought to result from noradrenergic overactivation and excess glucocorticoid release via hypothalamus-pituitary-adrenal axis stimulation. Instead of consecutive hypothalamus-pituitary-adrenal axis activation, we report that acute SCI in mice induced suppression of serum norepinephrine and concomitant increase in cortisol, despite suppressed adrenocorticotropic hormone, indicating primary (adrenal) hypercortisolism. This neurogenic effect was more pronounced after high-thoracic level (Th1) SCI disconnecting adrenal gland innervation, compared with low-thoracic level (Th9) SCI. Prophylactic adrenalectomy completely prevented SCI-induced glucocorticoid excess and lymphocyte depletion but did not prevent pneumonia. When adrenalectomized mice were transplanted with denervated adrenal glands to restore physiologic glucocorticoid levels, the animals were completely protected from pneumonia. These findings identify a maladaptive sympathetic-neuroendocrine adrenal reflex mediating immunosuppression after SCI, implying that therapeutic normalization of the glucocorticoid and catecholamine imbalance in SCI patients could be a strategy to prevent detrimental infections.
Collapse
Affiliation(s)
- Harald Prüss
- Department of Microbiology and Immunobiology, Division of Immunology, Harvard Medical School, Boston, Massachusetts, USA.,Department of Neurology and Experimental Neurology, Clinical and Experimental Spinal Cord Injury Research (Neuroparaplegiology), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.,German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
| | - Andrea Tedeschi
- Boston Children's Hospital, F.M. Kirby Neurobiology Center, Center for Life Science, Harvard Medical School, Boston, Massachusetts, USA.,German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.,Center for Brain and Spinal Cord Repair, Department of Neuroscience, The Neurological Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Aude Thiriot
- Department of Microbiology and Immunobiology, Division of Immunology, Harvard Medical School, Boston, Massachusetts, USA
| | - Lydia Lynch
- Department of Microbiology and Immunobiology, Division of Immunology, Harvard Medical School, Boston, Massachusetts, USA
| | - Scott M Loughhead
- Department of Microbiology and Immunobiology, Division of Immunology, Harvard Medical School, Boston, Massachusetts, USA
| | - Susanne Stutte
- Department of Microbiology and Immunobiology, Division of Immunology, Harvard Medical School, Boston, Massachusetts, USA.,Institute for Immunology, Biomedical Center, Ludwig-Maximilians-University Munich, Martinsried, Germany
| | - Irina B Mazo
- Department of Microbiology and Immunobiology, Division of Immunology, Harvard Medical School, Boston, Massachusetts, USA
| | - Marcel A Kopp
- Department of Neurology and Experimental Neurology, Clinical and Experimental Spinal Cord Injury Research (Neuroparaplegiology), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Benedikt Brommer
- Department of Neurology and Experimental Neurology, Clinical and Experimental Spinal Cord Injury Research (Neuroparaplegiology), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.,Boston Children's Hospital, F.M. Kirby Neurobiology Center, Center for Life Science, Harvard Medical School, Boston, Massachusetts, USA
| | - Christian Blex
- Department of Neurology and Experimental Neurology, Clinical and Experimental Spinal Cord Injury Research (Neuroparaplegiology), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Laura-Christin Geurtz
- Department of Neurology and Experimental Neurology, Clinical and Experimental Spinal Cord Injury Research (Neuroparaplegiology), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Thomas Liebscher
- Treatment Centre for Spinal Cord Injuries, Trauma Hospital Berlin, Berlin, Germany
| | - Andreas Niedeggen
- Treatment Centre for Spinal Cord Injuries, Trauma Hospital Berlin, Berlin, Germany
| | - Ulrich Dirnagl
- Department of Neurology and Experimental Neurology, Clinical and Experimental Spinal Cord Injury Research (Neuroparaplegiology), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.,German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
| | - Frank Bradke
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
| | - Magdalena S Volz
- Department of Gastroenterology, Infectiology and Rheumatology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Michael J DeVivo
- National Spinal Cord Injury Statistical Center, Department of Physical Medicine and Rehabilitation, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Yuying Chen
- National Spinal Cord Injury Statistical Center, Department of Physical Medicine and Rehabilitation, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Ulrich H von Andrian
- Department of Microbiology and Immunobiology, Division of Immunology, Harvard Medical School, Boston, Massachusetts, USA
| | - Jan M Schwab
- Department of Neurology and Experimental Neurology, Clinical and Experimental Spinal Cord Injury Research (Neuroparaplegiology), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.,Department of Neurology and Neuroscience, Center for Brain and Spinal Cord Repair, Department of Physical Medicine and Rehabilitation, The Neurological Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| |
Collapse
|
45
|
Cugno M, Tedeschi A, Frossi B, Bossi F, Marzano AV, Asero R. Detection of Low-Molecular-Weight Mast Cell-Activating Factors in Serum From Patients With Chronic Spontaneous Urticaria. J Investig Allergol Clin Immunol 2017; 26:310-313. [PMID: 27763857 DOI: 10.18176/jiaci.0051] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND AND OBJECTIVES Functionally active autoantibodies to IgE and to the high-affinity IgE receptor (FcεRI) can be detected in serum in about 40% of patients with chronic spontaneous urticaria (CSU). Recent studies showed that serum from patients with CSU can induce activation of mast cells, irrespective of whether they carry high-affinity IgE receptors. To evaluate mast cell activation induced by factors in the serum of CSU patients with a molecular weight lower than that of autoantibodies. METHODS Eight CSU patients and 5 healthy controls were evaluated. Whole serum and serum fractionated at 100, 50, and 30 kDa were used to stimulate in vitro LAD2 mast cells. The enzymatic activity of β-hexosaminidase was evaluated in supernatants and cell pellets as a measure of mast cell degranulation. RESULTS Mean (SEM) release of mast cell β-hexosaminidase induced by whole serum from CSU patients was higher than that induced by serum from the healthy controls (14.4 [2.7%] vs 5.1 [2.4%]; P=.027). In addition, serum fractions below 100 kDa and below 50 kDa from CSU patients induced mast cell degranulation that was significantly higher than that induced by the corresponding fractions in sera from healthy controls (10.2% [1.4%] vs 3.8% [1.9%] [P=.024] and 10.1% [1.2%] vs 3.9% [1.7%] [P=.012], respectively). In 4 CSU patients, we evaluated serum fractions <30 kDa, which retained their capacity to activate mast cells (11.0% [0.7%]). CONCLUSIONS This study shows that sera from CSU patients may contain low-molecular-weight mast cell-activating factors other than autoantibodies. These factors could be an additional mechanism contributing to the pathogenesis of CSU.
Collapse
Affiliation(s)
- M Cugno
- Medicina Interna, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy
| | - A Tedeschi
- SC Medicina Interna a Indirizzo Pneumologico, AO Fatebenefratelli e Oftalmico, Milano, Italy
| | - B Frossi
- Dipartmento di Scienze e Tecnologie Biomediche, Università di Udine, Udine, Italy
| | - F Bossi
- Dipartmento di Scienze Mediche, Chirurgiche e della Salute, Università di Trieste, Ospedale Universitario di Cattinara, Trieste, Italy
| | - A V Marzano
- Unità Operativa di Dermatologia, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy
| | - R Asero
- Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy
| |
Collapse
|
46
|
Cugno M, Mancuso ME, Tedeschi A, Santagostino E, Lorini M, Carbonelli V, Peyvandi F, Mannucci PM. Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis. Haemophilia 2017; 23:e348-e353. [DOI: 10.1111/hae.13282] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/28/2017] [Indexed: 12/20/2022]
Affiliation(s)
- M. Cugno
- Internal Medicine; Department of Pathophysiology and Transplantation; Università degli Studi di Milano; Milan Italy
- Angelo Bianchi Bonomi Hemophilia and Thrombosis Center; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Milan Italy
| | - M. E. Mancuso
- Angelo Bianchi Bonomi Hemophilia and Thrombosis Center; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Milan Italy
| | - A. Tedeschi
- Internal Medicine; Ospedale Fatebenefratelli e Oftalmico; Milan Italy
| | - E. Santagostino
- Angelo Bianchi Bonomi Hemophilia and Thrombosis Center; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Milan Italy
| | - M. Lorini
- Dipartimento di Scienze Cliniche e di Comunità; Università degli Studi di Milano; Milan Italy
| | - V. Carbonelli
- Dipartimento di Scienze Cliniche e di Comunità; Università degli Studi di Milano; Milan Italy
| | - F. Peyvandi
- Internal Medicine; Department of Pathophysiology and Transplantation; Università degli Studi di Milano; Milan Italy
- Angelo Bianchi Bonomi Hemophilia and Thrombosis Center; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Milan Italy
| | - P. M. Mannucci
- Angelo Bianchi Bonomi Hemophilia and Thrombosis Center; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Milan Italy
| |
Collapse
|
47
|
Herold M, Hoster E, Janssens A, McCarthy H, Tedeschi A, Pocock C, Rosta A, Schmidt P, Trněný M, Burciu A, Fingerle-Rowson G, Rufibach K, Zeuner H, Hiddemann W, Marcus R. IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN a SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_136] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Herold
- Oncology Center, HELIOS-Klinikum Erfurt; Erfurt Germany
| | - E. Hoster
- Department of Medicine III; Ludwig-Maximilians-University Hospital Munich; Munich Germany
| | - A. Janssens
- Department of Haematology; UZ Leuven; Leuven Belgium
| | - H. McCarthy
- Department of Haematology; Royal Bournemouth General Hospital; Bournemouth UK
| | - A. Tedeschi
- Division of Hematology; A. O. Ospedale Niguarda Ca’ Granda; Milan Italy
| | - C. Pocock
- Department of Haematology; Kent & Canterbury Hospital; Canterbury UK
| | - A. Rosta
- Department of Haematology, Országos Onkológiai Intézet; Budapest Hungary
| | - P. Schmidt
- Dr. med. Peter Schmidt; Praxis Neunkirchen/Saar Germany
| | - M. Trněný
- 1st Department of Medicine; Charles University General Hospital; Prague Czech Republic
| | - A. Burciu
- Pharma Development Safety and Risk Management; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - G. Fingerle-Rowson
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - K. Rufibach
- Pharma Development Biometrics Biostatistics; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - H. Zeuner
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - W. Hiddemann
- Department of Medicine III; Ludwig-Maximilians-University Hospital Munich; Munich Germany
| | - R. Marcus
- Department of Haematology; Kings College Hospital; London UK
| |
Collapse
|
48
|
Ghia P, Scarfò L, Coscia M, Sancetta R, Ferrario A, Tedeschi A, Farina L, Laurenti L, Orlandi E, Reda G, Motta M, Carlo Stella C, Massaia M, Quaresmini G, Rossini F, Ladetto M, Gaidano G, Rossi V, Montillo M. A MRD-GUIDED APPROACH FOR THE COMBINATION OF IBRUTINIB TO VENETOCLAX IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (IMPROVE STUDY). Hematol Oncol 2017. [DOI: 10.1002/hon.2440_11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P. Ghia
- Strategic Program on CLL; IRCCS Ospedale San Raffaele; Milan Italy
| | - L. Scarfò
- Strategic Program on CLL; IRCCS Ospedale San Raffaele; Milan Italy
| | - M. Coscia
- Division of Hematology, University of Torino; AOU Città della Salute e della Scienza di Torino; Torino Italy
| | - R. Sancetta
- U.O.C. Ematologia; Azienda ULSS 3 Serenissima; Mestre Italy
| | - A. Ferrario
- UOC Ematologia; Azienda Socio Sanitaria Territoriale dei Sette Laghi Ospedale di Circolo e Fondazione Macchi; Varese Italy
| | - A. Tedeschi
- Department of Haematology & Oncology Service of Haematology; Niguarda Cancer Center Niguarda Hospital; Milan Italy
| | - L. Farina
- Istituto Nazionale dei Tumori; Unità Trapianto di Midollo; Milan Italy
| | - L. Laurenti
- Policlinico A. Gemelli; Università Cattolica del Sacro Cuore; Rome Italy
| | - E. Orlandi
- S.C Ematologia; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - G. Reda
- UOC Oncoematologia; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico; Milan Italy
| | - M. Motta
- U.O. Ematologia; Spedali Civili di Brescia-Azienda Ospedaliera; Brescia Italy
| | - C. Carlo Stella
- Sezione di Ematologia; Cancer Center Humanitas; Rozzano Italy
| | - M. Massaia
- Struttura Complessa di Ematologia; Azienda Ospedaliera S. Croce e Carle di Cuneo; Cuneo
| | - G. Quaresmini
- Ematologia; Azienda Ospedaliera Papa Giovanni XXIII; Bergamo Italy
| | - F. Rossini
- Divisione di Ematologia e Trapianto di Midollo, Ospedale S. Gerardo; Universita' di Milano Bicocca; Monza Italy
| | - M. Ladetto
- Ematologia; Presidio Ospedaliero SS Antonio e Biagio; Alessandria Italy
| | - G. Gaidano
- Divisione di Ematologia; Università del Piemonte Orientale "Amedeo Avogadro"; Novara Italy
| | - V. Rossi
- Hematology & Transfusion Medicine; L. Sacco University Hospital & School of Medicine; Milan Italy
| | - M. Montillo
- Department of Haematology & Oncology Service of Haematology; Niguarda Cancer Center Niguarda Hospital; Milan Italy
| |
Collapse
|
49
|
Frigeni M, Visco C, Besson C, Rattotti S, Fontaine H, Goldaniga M, Visentini M, Torres H, Peveling-Oberhag J, Rossotti R, Zaja F, Rigacci L, Merli M, Dorival C, Alric L, Piazza F, Gentile M, Ferrari A, Pirisi M, Tedeschi A, Defrancesco I, Ferretti V, Bruno R, Hermine O, Arcaini L. INTERFERON-FREE ANTIVIRAL TREATMENT IN B-CELL LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS INFECTION. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Frigeni
- Department of Molecular Medicine; University of Pavia; Pavia Italy
| | - C. Visco
- Department of Cell Therapy and Hematology; San Bortolo Hospital; Vicenza Italy
| | - C. Besson
- Université Paris Sud, INSERM; Assistance Publique-Hôpitaux de Paris Centre Hospitalier Universitaire Bicêtre; Le Kremlin-Bicêtre France
| | - S. Rattotti
- Department of Hematology Oncology; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; Pavia Italy
| | - H. Fontaine
- Paris 5 Descartes University; INSERM U1213 and Unité Mixte de Service 20; Institut Pasteur, Department of Hepatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris; Paris France
| | - M. Goldaniga
- Department of Hematology, Fondazione Ospedale Maggiore Policlinico; Mangiagalli e Regina Elena; Milan Italy
| | - M. Visentini
- Division of Clinical Immunology; Sapienza University of Rome, Fondazione Roma; Rome Italy
| | - H.A. Torres
- Department of Infectious Diseases, Infection Control, and Employee Health; The University of Texas MD Anderson Cancer Center; Houston Texas USA
| | - J. Peveling-Oberhag
- Department of Internal Medicine 1; Goethe-University Hospital; Frankfurt Germany
| | - R. Rossotti
- Department of Infectious Diseases; Ospedale Niguarda Ca’ Granda; Milan Italy
| | - F. Zaja
- Hematology Unit, Centro Trapianti e Terapie Cellulari Carlo Melzi, DISM, Azienda Sanitaria Universitaria Integrata; Udine Italy
| | - L. Rigacci
- Department of Hematology; Azienda Ospedaliero-Universitaria Careggi; Florence Italy
| | - M. Merli
- Division of Hematology, Ospedale di Circolo e Fondazione Macchi; University of Insubria; Varese Italy
| | - C. Dorival
- Sorbonne Universités, Pierre and Marie Curie University (University of Paris 06), INSERM; Institut Pierre Louis d'épidémiologie et de Santé Publique (Unité mixte de recherche S1136); Paris France
| | - L. Alric
- Toulouse 3 University, Unité mixte de recherche 152 Institut de Recherche pour le Développement; Department of Internal Medicine and Digestive Diseases, Hôpital Purpan; Toulouse France
| | - F. Piazza
- Hematology and Clinical Immunology Unit, Department of Medicine; University of Padua; Padua Italy
| | - M. Gentile
- Hematology Unit; Azienda Ospedaliera di Cosenza; Cosenza Italy
| | - A. Ferrari
- Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico; Reggio Emilia Italy
| | - M. Pirisi
- Department of Translational Medicine; Università degli Studi del Piemonte Orientale "A. Avogadro"; Novara Italy
| | - A. Tedeschi
- Department of Hematology, Niguarda Cancer Center, Ospedale Niguarda Ca’ Granda; Milan Italy
| | - I. Defrancesco
- Department of Molecular Medicine; University of Pavia; Pavia Italy
| | - V.V. Ferretti
- Department of Molecular Medicine; University of Pavia; Pavia Italy
| | - R. Bruno
- Division of Infectious and Tropical Diseases, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; Pavia Italy
| | - O. Hermine
- Paris 5 Descartes University; AP-HP, Department of Adult Hematology and Imagine Institute, Hôpital Necker; Paris France
| | - L. Arcaini
- Department of Hematology Oncology; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; Pavia Italy
| |
Collapse
|
50
|
Buske C, LeBlond V, Novotny W, Owen R, Tedeschi A, Atwal S, Cohen A, Huang J, Tam C. A HEAD-TO-HEAD PHASE 3 STUDY COMPARING BGB-3111 AND IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA. Hematol Oncol 2017. [DOI: 10.1002/hon.2440_5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- C. Buske
- Institute of Experimental Cancer Research & Department of Internal Medicine III; University Hospital, Ulm; Ulm Germany
| | - V. LeBlond
- Hematology; Pitié Salpêtrière Hospital; Paris France
| | - W. Novotny
- Research and Development Center, BeiGene; Beijing and Emeryville; CA, US China
| | - R. Owen
- Haematology, St. James's University Hospital; Leeds UK
| | - A. Tedeschi
- Division of Hematology; Niguarda Cancer Center; Milan Italy
| | - S. Atwal
- Research and Development Center, BeiGene; Beijing and Emeryville; CA, US China
| | - A. Cohen
- Research and Development Center, BeiGene; Beijing and Emeryville; CA, US China
| | - J. Huang
- Research and Development Center, BeiGene; Beijing and Emeryville; CA, US China
| | - C.S. Tam
- Haematology; St. Vincent's Hospital; Melbourne Australia
| |
Collapse
|